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Summary 
Introduction 
Health Problem 
Sepsis, septic shock and SIRS are life-threatening conditions associated with 
an overreacting immune response. The dysregulated response can lead to 
multiple organ dysfunction. While sepsis and septic shock have an infec-
tious origin, SIRS may also have non-infectious triggers such as cardiac sur-
gery using the Cardiopulmonary Bypass (CPB). This is of particular interest 
for this report. SIRS, sepsis and septic shock have a mortality of an estimat-
ed 7, 16 and 40% respectively [1].  
The new 2016 Sepsis-3 definition has two grades: sepsis and septic shock [1]. 
The previous sepsis definitions published in 1992 emphasized on the role of 
systemic inflammatory response syndrome (SIRS) as a key element of the sep-
sis definition. However, evidence showed that SIRS criteria are non-specific 
and insensitive as predictor for sepsis related mortality, thus are not includ-
ed in the most recent international sepsis definitions. The members of the 
Sepsis-3 taskforce suggested that sepsis should be considered in the event of 
an infectious process associated with an increase in SOFA score of two points 
or more. Patients with septic shock would be clinically identified by a vaso-
pressor requirement to maintain a mean arterial pressure of 65 mmHg or 
greater, and serum lactate level greater than 2 mmol/l (>18 mg/dl) in the ab-
sence of hypovolemia. SIRS patients are identified by fulfilling two or more 
of the four SIRS criteria. 
The two main therapeutic priorities include early identification of a poten-
tial infectious origin and haemodynamic stabilisation of the patient. Other 
than the control of the primary site of infection, there is no causal treatment 
for sepsis, septic shock or SIRS [2].  
Description of Technology 
Extracorporeal Cytokine Adsorption Therapy (ECAT) aims to reduce the 
levels of cytokines in the blood. Cytokines are signalling molecules that are 
produced during an immune response. In sepsis, septic shock and SIRS this 
response is dysregulated resulting in an excessive release of cytokines that 
trigger further immune cascades. ECAT intends to adsorb the cytokines from 
the blood to restore a balanced immune response. Adsorption therapy is an 
addition to standard treatment of sepsis or SIRS. ECAT is not recommend-
ed by the most recent international sepsis guidelines.  
Currently, CytoSorb® is the only ECAT device that received CE marked au-
thorization to enter the EU market. The device consists of a single-use car-
tridge that can be used as stand-alone therapy and in combination with dia-
lyses machines, and heart-lung machines. The absorber cartridge is filled with 
sorbent beads, which adsorb the cytokines as they pass through the blood 
pump.  
The patient blood is continuously recirculated between the absorption device 
and the patient up to maximum 24 hours; afterwards the cartridge needs to 
be replaced. The typical treatment duration for sepsis patients is 48 hours to 
72 hours. The use of CytoSorb® during CPB surgery is recommended for a 
CPB duration of more than >120 min.  
Sepsis, septischer  
Schock und SIRS sind 
lebensbedrohliche, 
systemische 
Immunreaktionen 
neue 2016  
Konsensus-Leitlinien für 
die Definition von Sepsis 
und septischem Schock 
 
Veränderung in SOFA 
Score um 2 Punkte führt 
zur Diagnose der Sepsis 
 
>2 der 4 SIRS Kriterien 
zur Diagnose von SIRS 
Therapie: 
Hämodynamische 
Stabilisierung und 
antibiotische Abdeckung 
Extrakorporale Zytokin 
Adsorption versucht 
Zytokinkonzentration 
zu vermindern; 
Zusatz zur 
Standardtherapie; 
derzeit von Leitlinien 
nicht empfohlen 
Einmal-Kartusche 
in Kombination  
mit Dialyse und 
Herzlungenmaschine 
verwendbar 
Therapiedauer:  
48-72 h therapeutisch,  
> 2 h präventiv 
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Methods 
The focus of this assessment was the evaluation of efficacy and safety of ex-
tracorporeal haemadsorption therapy in patients with sepsis and Systemic In-
flammatory Response Syndrome (SIRS), as well as its preventive use for pa-
tients at risk of developing SIRS following cardiopulmonary bypass surgery.  
To answer the research questions on efficacy and safety-related outcomes a 
systematic literature search in five databases was conducted, without re-
striction on the search strings. In addition, we performed a hand search and 
screened information provided by the manufacturer and submitting hospital 
to identify further relevant studies. The study selection, data extraction and 
assessing the methodological quality of the studies was performed by two in-
dependent researchers. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a re-
commendation: improved survival (mortality), improved clinical outcomes, 
days spent in the ICU, and total days of hospitalization.  
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: adverse events (AE) and serious adverse events (SAE). 
 
Results 
Available evidence 
We could identify one randomised-controlled trial and one retrospective case 
series to assess efficacy of ECAT as preventive intervention during CPB sur-
gery. The total number of patients was 77 of which 39 received CytoSorb® 
therapy. Both studies assessed the preventive use of CytoSorb® during CPB 
surgery.  
To assess safety outcomes, one additional retrospective case series was iden-
tified (N=16). Similarly as the two other studies, it assessed the use of Cyto-
Sorb® in SIRS patients, yet, therapeutic following CPB surgery.  
We could not identify any controlled study on ECAT as therapeutic addition 
to the treatment of sepsis.  
Clinical effectiveness 
Regarding the crucial outcomes for effectiveness, one study, a randomised 
controlled trial (RCT) with 37 patients assessed mortality and improved sur-
vival as secondary outcome measure. One out of 19 patients in the interven-
tion group died on the 22nd postoperative day, while all 18 patients in the con-
trol group survived the 30 days. The study found no significant differences 
in the length of stay in intensive care units and in the days of mechanical 
ventilation. The retrospective case series including 40 patients did not report 
on any of the crucial effectiveness outcomes. None of the studies reported on 
the total days of hospitalization or on changes in SOFA score, MODS score, 
or another measure to assess organ failure. 
Fragestellung 
systematische 
Literatursuche 
entscheidende 
Endpunkte für 
Wirksamkeit 
und Sicherheit 
1 RCT, 2 retrospektive 
Fallserien 
 
Insgesamt 93 Patienten, 
55 bekamen ECAT  
keine Studie zu  
Therapie der Sepsis 
Daten zur Wirksamkeit: 
keine signifikanten 
Ergebnisse in allen 
wichtigen Endpunkten  
 
wichtige Endpunkte  
nur von einer Studie 
berichtet 
Summary 
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Safety 
None of the studies reported on adverse or serious adverse events for the use 
of CytoSorb® during CPB surgery or post-operative. In total, the technology 
was use in 55 patients. Furthermore, no adverse device effects were described.  
Upcoming evidence 
In total, we identified seven relevant ongoing trials and one patient registry. 
Two of the ongoing trials assess the use of CytoSorb® in patients with sepsis, 
while the others focus on its preventive use during CPB surgery.  
Reimbursement 
Currently, ECAT is not reimbursed by the Austrian health care system, nei-
ther as treatment of sepsis, septic shock or SIRS, nor as preventive treatment 
during CPB surgery. 
 
Discussion 
ECAT is a new technology with very limited clinical evidence available. On-
ly one study met our initial inclusion criteria, and thus, all studies that pro-
vided clinical data of more than five patients were included.  
There was no data on the effect or safety of ECAT in patients with sepsis 
and septic shock. Moreover, the strength of evidence is very low for the pre-
ventive use of ECAT during CPB surgery. Although we could identify one 
randomised study, the risk of bias of this study was high, due to a small sam-
ple size, insufficient blinding, and a high rate of loss to follow-up (30%). The 
study sample of the RCT was not powered to draw conclusions on mortality, 
or other patient-relevant benefits. Only one of the two observational studies 
included a control group, however, failed to state patient characteristics or 
report on crucial outcomes. Furthermore, considering the various potential 
adverse effects of ECAT, safety endpoints were not reported by any of the 
studies, and only mentioned in the discussion. The number of patients includ-
ed in the studies was small, and stemmed entirely from single centre studies. 
In view of the small study population and the two different indications, the 
results of the studies cannot be generalised to a larger population. 
 
Conclusion 
The current evidence does not suffice to prove that ECAT in patients with 
sepsis, septic shock and SIRS is effective and safe. Clinical benefits in terms 
of patient-relevant outcomes in both indications need to be demonstrated in 
order to introduce ECAT into practice. A re-evaluation is recommended in 
2019, if results from RCTs or CT including more than 100 patients are avail-
able.  
 
 
  
keine Daten zu AE  
oder SAE berichtet  
7 kontrollierte Studien 
und eine Registerstudie 
derzeit nicht 
rückerstattet 
neue Technologie mit 
sehr wenig Evidenz 
 
keine Daten zur 
Wirksamkeit bei Sepsis, 
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präventiven Anwendung 
 
Qualität der Evidenz 
sehr niedrig da 
hohes Bias Risiko 
geringe Fallzahl 
fehlende Verblindung 
und Kontrollgruppen 
 
Sicherheitsendpunkte 
nicht berichtet 
Evidenz unzureichend: 
Aufnahme nicht 
empfohlen 
 
Re-Evaluierung: 2019 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Sepsis, septischer Schock und SIRS sind lebensbedrohliche Zustände, die 
durch eine Überreaktion des Immunsystems ausgelöst werden. Während Sep-
sis und septischer Schock infektiösen Ursprungs sind, kann SIRS auch nicht-
infektiöse Auslöser – wie Herzchirurgische Eingriffe unter Verwendung der 
Herz-Lungen-Maschine (HLM) (kardiopulmonaler Bypass (CPB)) – haben. 
Dies ist für den vorliegenden Bericht von besonderer Bedeutung. Die Ver-
wendung der HLM kann eine systemische Entzündungsreaktion während der 
Operation hervorrufen, die durch Kontaktaktivierung des Blutes durch künst-
liche Oberflächen ausgelöst wird. 
Die dysregulierte Überreaktion des Immunsystems auf eine Infektion oder 
andere Stimuli kann zu multiplen Organdysfunktionen führen. SIRS, Sepsis 
und septischer Schock haben eine geschätzte Mortalitätsrate von jeweils 7, 
16 bzw. 40 %[1]. 
Die im Jahr 2016 aktualisierte „Internationale Konsensus Leitlinie zur De-
finition und Diagnose der Sepsis“ (SCCM/ESICM consensus guideline) enthält 
Empfehlungen zur Beurteilung der Organdysfunktion von PatientInnen mit 
vermuteter Sepsis. Die Beurteilung sollte mit dem qSOFA (quick Sepsis-
bezogenem Organ-Dysfunktions Score) beziehungsweise dem vollen SOFA-
Score erfolgen (siehe Table 4-1) [1]. 
Für die Diagnose des SIRS (Systemic Inflammatory Response Syndrom) 
müssen mindestens zwei der vier SIRS Kriterien erfüllt sein [3]:  
 erhöhte oder verminderte Körpertemperatur,  
 erhöhte oder verminderte Leukozytenzahl 
 Tachykardie (Herzrasen) 
 erhöhte Atemfrequenz. 
PatientInnen mit SIRS oder vermuteter Sepsis weisen eine Kombination di-
verser Symptome auf. Die Symptome reichen von einem niedrigen Blutdruck, 
Fieber oder einer Körpertemperatur unter 36° C, bis hin zu einer hohen Atem-
frequenz, einer beschleunigten Herzfrequenz, einem veränderten mentalen 
Status und Anzeichen einer Hypoperfusion.  
Die beiden wichtigsten therapeutischen Prioritäten sind die frühzeitige Iden-
tifizierung eines potenziellen infektiösen Ursprungs und die hämodynami-
sche Stabilisierung der PatientInnen. Abseits der frühen antibiotischen Ab-
schirmung, gibt es derzeit keine kausale Behandlung für Sepsis, septischem 
Schock oder SIRS[2]. 
Beschreibung der Technologie 
Extrakorporale Zytokinadsorptionstherapie (ECAT) zielt darauf ab, die Zy-
tokinkonzentration im Blut zu reduzieren. Zytokine sind Signalmoleküle, die 
bei einer physiologischen Immunantwort produziert werden. Bei Sepsis, sep-
tischem Schock und SIRS kommt es zu einer Überreaktion, was zu einer er-
höhten Freisetzung der Zytokine führt, die ihrerseits wiederum weitere Im-
munkaskaden auslösen. Ziel der ECAT ist es, Zytokine aus dem Blut zu ent-
fernen, um eine balancierte Immunantwort wiederherzustellen.  
Sepsis, septischer Schock 
und SIRS sind 
lebensbedrohliche, 
systemische 
Immunreaktionen 
Mortalität 7-40 % 
Diagnose von Sepsis 
mittels SOFA score 
Diagnose von SIRS:  
2 von 4 Kriterien 
Symptomkombination 
Therapie: 
hämodynamische 
Stabilisierung und 
antibiotische Abdeckung 
extrakorporale 
Zytokinadsorption 
versucht 
Zytokinkonzentration 
im Blut zu vermindern 
Zusammenfassung 
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ECAT ist als Ergänzung zur Standardbehandlung von Sepsis oder SIRS vor-
gesehen. Die therapeutische Anwendung von ECAT ist in den jüngsten in-
ternationalen Konsensus-Leitlinien nicht empfohlen.  
Derzeit ist CytoSorb® das einzige ECAT-Gerät, das über eine CE- Zertifizie-
rung verfügt. Das Produkt besteht aus einer Einmal-Kartusche, die als Stand-
Alone Therapie oder in Kombination mit Dialysemaschinen und HLM ein-
gesetzt werden kann. Die Kartusche ist mit porösen Polymer-Adsorptions-
beads gefüllt, die Zytokine, und andere Entzündungsmediatoren ähnlicher 
Größe (Moleküle bis zu einer Größe von 55 kD) adsorbieren.  
Das Blut zirkuliert bis zu maximal 24 Stunden kontinuierlich zwischen dem 
Absorptionsgerät und der/m PatientIn, wonach die Kartusche ausgetauscht 
werden muss. Die typische Behandlungsdauer mit ECAT beträgt 48 bis 72 
Stunden für PatientInnen mit Sepsis. Die präventive Anwendung während 
eines herzchirurgischen Eingriffs mit einer HLM wird für eine CPB-Dauer 
von >120 min empfohlen. 
 
Methoden 
Im folgenden Bericht gingen wir der Frage nach, ob extrakorporale Zytokin-
adsorptionstherapie (ECAT) als therapeutischer Zusatz zur Standardthera-
pie für PatientInnen mit Sepsis, septischem Schock und SIRS wirksam und 
sicher ist. Des Weiteren wurden die Wirksamkeit und Sicherheit einer prä-
ventiven Zytokinadsorptionstherapie bei herzchirurgischen Eingriffen mit 
Einsatz der HLM geprüft.  
Zur Beantwortung der Forschungsfragen, wurde eine systematische Litera-
tursuche in fünf Datenbanken durchgeführt (Medline via Ovid, Embase, the 
Cochrane Library, CRD). Ergänzend erfolgten eine Suche in Studienregistern, 
eine Studienanfrage bei den Herstellern, sowie eine unsystematische Hand-
suche. Die Daten der entscheidungsrelevanten Endpunkte wurden aus den 
einzelnen Studien zusammengefasst und nach GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) bewertet. 
Die Studienauswahl, Datenextraktion sowie die Bewertung der methodischen 
Qualität der Studien wurde von zwei Autorinnen (KH, CW) unabhängig von-
einander durchgeführt.  
Klinische Wirksamkeit 
Die folgenden Endpunkte wurden für die Bewertung der Wirksamkeit als ent-
scheidend definiert: Verbesserung des Überlebens, klinische Verbesserung der 
Organdysfunktion, Aufenthaltsdauer in intensivmedizinischen Stationen, Ver-
minderung der Hospitaliserungsdauer.  
Sicherheit 
Die folgenden Endpunkte wurden für die Bewertung der Sicherheit als ent-
scheidend definiert: schwere unerwünschte Ereignisse (SAE), und unerwünsch-
te Ereignisse (AE). 
 
als Zusatz zur 
Standardtherapie;  
in Leitlinien derzeit 
nicht empfohlen 
 
Einmal-Kartusche 
in Kombination mit 
Dialyse und HLM 
verwendbar 
Therapiedauer:  
48-72 h therapeutisch, 
>2 h präventiv 
Fragestellung 
systematische 
Literatursuche in  
5 Datenbanken, 
Handsuche, 
Studienregister Suche 
 
Bewertung der Qualität 
mit GRADE 
entscheidende 
Endpunkte:  
Wirksamkeit: 
Überleben,  
klinische Verbesserung, 
Hospitalisierung 
Sicherheit: 
Komplikationsraten 
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Ergebnisse 
Verfügbare Evidenz 
Insgesamt konnten drei Studien identifiziert werden, in denen klinische Da-
ten zu ECAT erhoben wurden. Die Gesamtzahl der PatientInnen betrug 93, 
von denen 55 PatientInnen eine CytoSorb® Therapie erhielten. Für die Be-
urteilung der Wirksamkeit von ECAT wurde eine randomisierte kontrollierte 
Studie (RCT) und eine retrospektive Fallserie eingeschlossen. Beide Studien 
untersuchten die präventive Anwendung von CytoSorb® während herzchirur-
gischer Eingriffe mit HLM. 
Für die Bewertung der sicherheitsbezogenen Endpunkte konnte zusätzlich 
eine retrospektive Ein-Arm-Fallserie identifiziert werden. Die Fallserie mit 
insgesamt 16 Patienten berichtete über die Anwendung von ECAT bei Pati-
entInnen mit SIRS nach herzchirurgischen Eingriffen mit HLM.  
Zur therapeutischen Anwendung von ECAT bei Sepsis konnte keine kontrol-
lierte Studie identifiziert werden. 
Klinische Wirksamkeit 
Ein RCT mit 37 PatientInnen berichtete von einer 30-Tage Mortalität als se-
kundären Endpunkt. Ein/e der 19 PatientInnen der Interventionsgruppe ver-
starb am 22. postoperativen Tag, während alle 18 PatientInnen in der Kon-
trollgruppe eine Überlebensdauer von mindestens 30 Tagen hatten. Die Stu-
die wies darüber hinaus keine signifikanten Unterschiede bei der Aufenthalts-
dauer in Intensivstationen und bei den Tagen der mechanischen Beatmung 
auf.  
Die retrospektive Fallserie mit 40 PatientInnen enthielt keine Daten zu den 
empfehlungsrelevanten Endpunkten. Des Weiteren berichtete keine der Stu-
dien über die Gesamtdauer des Krankenhausaufenthaltes oder über Ände-
rungen im SOFA Score zur Beurteilung des Organversagens. 
Sicherheit 
Keine der Studien berichtete explizit über unerwünschte oder schwerwiegen-
de Ereignisse bei der Anwendung von CytoSorb® während der Herzchirurgie 
oder postoperativ bei PatientInnen mit SIRS. Darüber hinaus wurden keine 
unerwünschten produktbezogenen Ereignisse beschrieben. 
Zur therapeutischen Anwendung bei Sepsis konnten keine Daten identifiziert 
werden. 
Laufende Studien 
Insgesamt konnten sieben laufende Studien und ein PatientInnenregister 
identifiziert werden. Zwei der laufenden Studien beurteilen die Verwendung 
von CytoSorb® bei PatientInnen mit Sepsis, während die anderen sich auf den 
präventiven Einsatz während der Herzchirurgie mit HLM konzentrieren. 
Kostenerstattung 
Derzeit wird ECAT vom österreichischen Gesundheitssystem nicht erstattet.  
 
1 RCT,  
2 retrospektive Fallserien 
 
insgesamt 93 Patienten, 
55 bekamen ECAT  
keine Studie zur 
Therapie der Sepsis 
Daten zur Wirksamkeit: 
keine signifikanten 
Ergebnisse in allen 
wichtigen Endpunkten  
 
 
wichtige Endpunkte  
nur von einer Studie 
berichtet 
keine Daten zu 
unerwünschten 
Ereignissen und 
Nebenwirkungen  
7 kontrollierte Studien 
und eine Registerstudie 
derzeit keine Erstattung 
Zusammenfassung 
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Diskussion 
ECAT ist eine neue Technologie, für die wenig klinische Evidenz verfügbar 
ist. Nur eine Studie erfüllte die ursprünglichen Einschlusskriterien, worauf-
hin alle Studien, die klinische Daten von mehr als fünf PatientInnen ent-
hielten, eingeschlossen wurden, um die Technologie bewerten zu können.  
Aus den Studien gehen keine Daten zur Wirksamkeit oder Sicherheit von 
ECAT bei PatientInnen mit Sepsis und septischem Schock hervor. Darüber 
hinaus ist die Stärke der Evidenz eines präventiven Einsatzes von ECAT in 
die HLM sehr gering. Es konnte ein RCT identifiziert werden, allerdings wies 
diese ein hohes Bias Risiko, aufgrund einer zu geringen Stichprobengröße, 
unzureichender Verblindung und einem hohen Loss to follow up (30 %), auf. 
Eine schlussfolgernde Aussage über den Endpunkt Mortalität oder andere pa-
tientenrelevante Endpunkte können aufgrund geringer Power nicht getroffen 
werden. Nur eine der beiden Beobachtungsstudien umfasste eine Kontroll-
gruppe, jedoch berichtete diese weder von PatientInnencharakteristiken noch 
von entscheidenden Ergebnissen. Darüber hinaus wurden relevante Sicher-
heitsendpunkte von keiner der Studien explizit analysiert sondern lediglich 
in den Diskussionen erwähnt. In Anbetracht der verschiedenen potenziellen 
nachteiligen Auswirkungen von ECAT hebt dies die geringe Evidenzlage be-
sonders hervor. Angesichts der kleinen Studienpopulation und der zwei un-
terschiedlichen Indikationen können die Ergebnisse der Studien nicht auf 
eine größere Population verallgemeinert werden. 
 
Empfehlung 
Die gegenwärtige Studienlage lässt keine Rückschlüsse zu, ob eine Behand-
lung mittels ECAT bei Sepsis, septischem Schock oder SIRS wirksam oder 
sicher ist. Gleichsam ist auch für den präventiven Einsatz von ECAT bei kar-
diopulmonalen Bypass Operationen zu wenig Evidenz vorhanden, um die 
Wirksamkeit und Sicherheit der Intervention bewerten zu können.  
Neue Studien werden möglicherweise einen wichtigen Einfluss auf die Ein-
schätzung des Effekts haben. Eine neuerliche Evaluierung wird im Jahr 2019 
vorgeschlagen, jedoch nur wenn neue Ergebnisse aus RCT’s für beide Indi-
kationen vorliegen und diese mehr als 100 eingeschlossenen PatientInnen um-
fassen. Die Aufnahme in den Leistungskatalog wird derzeit nicht empfohlen. 
 
neue Technologie  
mit sehr wenig Evidenz 
 
keine Daten zur 
Wirksamkeit bei Sepsis, 
nur geringe Daten zur 
präventiven Anwendung 
 
Qualität der Evidenz 
sehr niedrig da 
hohes Bias Risiko 
geringe Fallzahl 
fehlende Verblindung 
und Kontrollgruppen 
 
Sicherheitsendpunkte 
nicht berichtet 
Evidenz unzureichend: 
Aufnahme nicht 
empfohlen 
Re-evaluierung  
2019  
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1 Scope 
1.1 PICO question 
Is extracorporeal cytokine adsorption therapy (ECAT) as addition to stand-
ard care in comparison to standard care alone in patients with SIRS, sepsis 
or septic shock as safe concerning adverse events, and more effective con-
cerning overall survival, organ function and recovery? 
Is ECAT as preventive therapy in patients undergoing cardiopulmonary by-
pass surgery (CPB) as safe concerning adverse events, and more effective con-
cerning overall survival, organ function and recovery? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population  Patients with SIRS, sepsis, septic shock (Abdominal septic, pneumonia with septic 
shock, septic arthritis, UTI) or SIRS (systemic inflammatory response syndrome) 
International Classification of diseases (ICD)-10 R65.20 Sepsis;  
Septic shock; R65.21 [1] 
 As preventive measure against SIRS in patients undergoing elective  
cardiopulmonary bypass surgery (CPB) 
Adults of all ages >18 
MeSH Terms: Severe Sepsis C01.539.757, C23.550.470.790.500;  
Septic Shock C01.539.757.800, C23.550.470.790.500.800, C23.550.835.900.712;  
SIRS C23.550.470.790, C23.550.835.900 
Intervention 1) Cytokine adsorption as therapeutic intervention in patients with SIRS,  
sepsis or septic shock 
2) Cytokine adsorption therapy as preventive intervention during cardiopulmonary 
bypass surgery 
Alternative terms (selection): 
 Hem(a)adsorption 
 haemadsorption 
 extracorporeal blood purification 
 extracorporeal cytokine adsorption 
 cytokine removal therapy 
 cytokine filter 
Product names: CytoSorb® (Cytosorbents) 
Control Standard care for SIRS sepsis and septic shock1, 
Standard care after coronary bypass surgery 
 
                                                             
1 Cytokine adsorption therapy serves as an addition to standard care, as defined in [2]. 
PIKO-Fragen: 
ECAT therapeutisch  
ECAT präventiv 
Einschlusskriterien  
für relevante Studien 
Extracorporeal cytokine haemadsorption therapy 
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Outcomes  
Efficacy Clinical endpoints: 
 Improved survival 
 Improved clinical outcomes: organ functions (Sepsis-related Organ Failure 
Assessment, SOFA score or Multiple Organ Dysfunction score, MODS) 
 Days in ICU 
 Days of hospitalization  
 Ventilator free days 
Surrogate endpoints: 
 Decrease in dose of vasopressor drugs 
 Decrease in blood cytokine levels 
Safety  Perioperative/periprocedural adverse events and complications  
 Postoperative/postprocedural adverse events and complications 
Study design  
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series, single arm studies 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is extracorporeal cytokine haemadsorption therapy(ECAT)? 
B0002 What is the claimed benefit of ECAT in relation to the comparator(s)? 
B0003 What is the phase of development and implementation of ECAT? 
B0004 Who administers ECAT and in what context and level of care is it provided? 
B0008 What kind of special premises are needed to use ECAT? 
B0009 What supplies are needed to use ECAT? 
A0020 For which indications has ECAT received marketing authorisation or CE marking? 
A0021 What is the reimbursement status of ECAT? 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is ECAT used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors forsepsis or SIRS? 
A0004 What is the natural course ofsepsis, septic shock or SIRS? 
A0005 What are the symptoms and the burden of disease or health condition for the patients? 
A0006 What are the consequences of sepsis for the society? 
A0024 How is sepsis and SIRS currently diagnosed according to published guidelines and in practice? 
A0025 How is the sepsis and SIRS currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is ECAT utilised? 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of ECAT on mortality? 
D0005 How does ECAT affect symptoms and findings (severity, frequency) of sepsis or SIRS? 
D0006 How does the technology affect progression (or recurrence) of sepsis or SIRS? 
D0011 What is the effect of ECAT on patients’ body functions? 
D0012 What is the effect of ECAT on generic health-related quality of life? 
D0013 What is the effect of ECAT on disease-specific quality of life? 
D0017 Were patients satisfied with ECAT? 
Safety 
Element ID Research question 
C0008 How safe is ECAT in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying ECAT? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use of ECAT? 
C0007 Is ECAT associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of ECAT? 
Extracorporeal cytokine haemadsorption therapy 
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2.2 Sources 
Description of the technology 
 Hand search in the POP, MDS, Synergus, Ohtanen and  
CRD databases for Health Technology Assessments 
 Background publications identified in database search:  
see Section 2.3 
 Hand search for background publications in UptoDate and  
Deximed databases 
 Documentation provided by the manufacturers 
Health problem and Current Use 
 Hand search in the POP, MDS, Synergus, Ohtanen and  
CRD databases for Health Technology Assessments 
 Background publications identified in database search:  
see Section 2.3 
 Hand search for treatment guidelines, epidemiologic data,  
national registries 
 Documentation provided by the manufacturers 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 23.12.2016  
in the following databases:  
 Medline via Ovid 
 PubMed 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was not limited to a specific study design, language or 
period. After deduplication, overall 592 citations were included. The specific 
search strategy employed can be found in the appendix.  
Manufacturers from the only CE-marked product CytoSorb® submitted a lit-
erature list with 32 publications of which 2 new citations were identified.  
By hand-search, an additional 24 studies were found, resulting in overall 618 
hits. 
  
Quellen 
systematische 
Literatursuche in  
5 Datenbanken  
insgesamt  
618 Publikationen 
identifiziert 
Methods 
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2.4 Flow chart of study selection 
Overall 616 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 
2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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 Additional records identified 
through other sources  
(n=26) 
Records after duplicates  
removed 
(n=618) 
Records screened 
(n=618) 
Records excluded 
(n=553) 
Full-text articles  
assessed for eligibility 
(n=65) Full-text articles excluded,  
with reasons  
(n=62) 
 Other intervention (n=5) 
 Conference abstracts,  
posters (n=11) 
 Other study design (n=3) 
 Case reports (n=17) 
 Ongoing studies, study 
protocols (n=2) 
 Background literature (n=24) 
Studies included in 
qualitative synthesis  
(n=3) 
 RCTs (n=1) 
 NRCTs (n=0) 
 Case-series (n=2) 
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2.5 Analysis 
We retrieved data from the selected studies (see Chapter 2.4) and systemati-
cally extracted them into the data-extraction-tables (see Appendix Table A-1 
and Table A-2). No further data processing (e.g. indirect comparison) was 
applied.  
Two independent researchers (KH, CW) systematically assessed the quality 
of evidence and risk of bias using the Cochrane Risk of Bias tool for RCTs 
and the IHE Risk of Bias checklist for case series [4]. The risk of bias analy-
sis for each individual study can be found in the Appendix (Table A-3 and 
Table A-4). 
 
 
2.6 Synthesis 
Due to the heterogeneity of studies, only a qualitative and not a quantitative 
analysis of efficacy and safety data was possible. The questions were answered 
in plain text format. 
In addition, a GRADE evidence table was created in order to synthesize data 
on each selected outcome category across studies (Table 7-1) [5]. Where avail-
able, data on critical outcomes were included in the evidence table.  
 
Datenextraktion  
aus Studien 
Qualitätsbeurteilung der 
Studien mit Cochrane 
RoB und IHE Checkliste 
qualitative Synthese  
der Evidenz 
Zusammenfassung der 
Ergebnisse mit GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is extracorporeal cytokine haemadsorption therapy? 
Extracorporeal cytokine adsorption therapy (ECAT) aims to reduce excessive 
levels of cytokines in the blood to control an overreacting systemic immune 
response of the body.  
The normal immune response to infection is a localised process aiming to 
control bacterial invasion. If this reaction becomes generalised and extends 
to normal tissue remote from the initial site of injury or infection a systemic 
inflammatory response ensues. The uncontrolled inflammatory process leads 
to an excessive release and overproduction of cytokines [6-8].  
Cytokines are small proteins (25kDa) that serve as signalling molecules dur-
ing an immune response. They are released by various cell types upon initial 
activating stimuli, such as endotoxin and lipopolysaccharides (LPS) on the 
bacterial cell wall. Cytokines can have pro-inflammatory as well as anti-in-
flammatory capacities. The number of identified cytokines is large and in-
creasing, while, to date, the underlying signalling pathways and various effects 
of different cytokines are not completely understood [6]. However, there is 
evidence that an elevated level of cytokines is associated with the development 
of a systemic inflammatory response syndrome (SIRS), and a poor prognosis 
[6, 9, 10].  
The main pro-inflammatory cytokines known today are Interleukin 1 (IL-1), 
IL-6, IL-8, Tumour Necrosis Factor α (TNF- α) and Macrophage Inflamma-
tory Protein-1 α (MIP-1 α). Studies have shown a correlation between the lev-
el of IL-6 and the severity of sepsis and subsequent mortality. Furthermore, 
an elevated level of IL-6 following cardiopulmonary bypass surgery(CPB) was 
associated with worsening lung function and the development of SIRS [9]. 
The simultaneous release of anti-inflammatory cytokines, such as IL-10 and 
IL-13, aims to balance and control an inflammatory response. The loss of con-
trol of this balanced, localised reaction leads to the systemic inflammation 
with potential detrimental consequences such as SIRS, sepsis and septic shock 
[8].  
The principal idea behind extracorporeal haemadsorption therapies is to re-
move these inflammatory molecules from the blood in order to restore a bal-
anced immune response [11]. Originally, extracorporeal blood purification 
therapies have been used in septic patients in order to replace the function 
of failing organs, for instance, to support the kidney or liver function. By 
adding an adsorbing haemofilter into the blood purification device, molecules 
from the blood are bound to the surface of the adsorber and eliminated from 
the blood [7].  
  
Extrakorporale Zytokin 
Adsorptions Therapie 
soll Zytokin Level  
im Blut bei 
überschießenden 
Immunantworten 
reduzieren 
Funktionsweise vieler 
Zytokine ist noch nicht 
bekannt 
Zytokine sind 
körpereignene Proteine, 
die bei Steuerung der 
Immunreaktionen als 
Signalmoleküle dienen 
Überschuss an  
Pro-inflammatorischen 
Zyktokinen (IL-6, IL-1, 
TNF- α) korreliert mit 
Sepsis Schweregrad  
und Mortalität 
simultane Freisetzung 
Anti-inflammatorischer 
Zytokine (IL-10, IL-13) 
führt zu balancierter 
Immunantwort 
ECAT:  
soll Überschuss an 
Zytokinen ausgleichen 
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Marketed Products 
Several cytokine adsorbing columns are currently being investigated for their 
potential in eliminating cytokines and other molecules from the blood:  
 CYT-860-DHP (Toray Industries, Inc., Tokyo, Japan),  
 Lixelle® (Kaneka Co., Osaka, Japan) 
 CTR-001 Column (Kaneka Co., Osaka, Japan)  
 MPCF-X and  
  CytoSorb® (Cytosorbents Co., USA) [12].  
These adsorptive columns vary in their structure and adsorption rate. Preclin-
ical studies have shown beneficial effects in survival rates in animal sepsis 
models [13].  
Currently, CytoSorb® is the only CE-marked extracorporeal haemadsorption 
device in the European Union (EU). CytoSorb® is a Class 2b medical device 
and received market authorization in 2011. It is marketed in almost all EU 
Member States, with the exception of eastern European countries. Globally, 
it is commercialised in 42 countries, amongst others in Australia, Chile, Rus-
sia, India, Saudi Arabia, India, and Turkey (Information by manufacturer).  
The device consists of a single-use haemadsorption cartridge that can be used 
as stand-alone therapy with standard blood pumps, in combination with con-
tinuous renal replacement therapy (CRRT) or during cardiopulmonary by-
pass (CPB) surgery.  
The adsorber cartridge is filled with sorbent, porous polymer beads of the size 
of a grain of salt. The beads capture and adsorb molecules as the blood pass-
es through the pump. Smaller molecules (5-60 kDa) such as pro- and anti-in-
flammatory cytokines get captured in the net of pores, while larger molecules 
can pass through [13].  
B0002 – What is the claimed benefit  
of ECAT in relation to the comparators? 
Rather than being a causal therapy for sepsis ECAT, is intended as an ad-
dition to standard treatment of sepsis. There is neither a direct comparator 
for the causal treatment of sepsis nor a standard therapeutic option to adsorb 
cytokines from the blood.  
The claimed major benefit for the use of cytokine adsorption is to reduce the 
level of cytokines and thus the inflammatory response.  
Other blood purification mechanisms were proposed to remove  
excessive levels of cytokines from the blood:  
 Haemoperfusion  
 Plasma or whole blood exchange 
 Coupled plasma filtration 
 High volume haemofiltration 
Several reviews exist that summarised the differences between the blood pu-
rification techniques and their suggested advantages and disadvantages [7, 
11, 13]. While there are some studies showing benefits for haemoperfusion, 
haemofiltration and plasma exchange, the results remain preliminary [14]. 
Furthermore, opposing studies showed limited or no clinical advantage [15].  
mehrere 
Adsorptionsträger 
derzeit untersucht 
Unterschiede in Aufbau 
und Adsorptionsrate 
CytoSorb® einziger 
Adsorber mit  
CE-Kennzeichnung  
(seit 2011) 
Klasse 2b 
Medizinprodukt 
Anwendung als  
Stand-alone Therapie 
oder in Kombination mit 
Nierenersatztherapie 
oder 
Herzlungenmaschine 
ECAT als Zusatz zur 
Standard Therapie; 
keine kausale Therapie 
bei Sepsis oder für 
Zytokinadsorption 
weitere 
Blutreinigungsverfahren 
jede Methode hat  
Vor- und Nachteile 
Ergebnisse aus 
klinischen Studien 
widersprüchlich 
Description and technical characteristics of technology 
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In summary, no clear evidence is available to date that verifies the efficacy and 
safety of these procedures [11, 13, 15]. The most recent international consen-
sus guideline on the management of sepsis does not recommend the use of 
any of the blood purification therapies, reasoning that the available trials are 
small, insufficiently blinded with a high risk of bias [2]. Larger randomised 
trials will be necessary to assess potential benefits and compare interventions 
with each other. 
In comparison to these techniques the claimed major advantage of the Cyto-
Sorb® device is its large surface of area of 40,000 m² compared to classic hae-
mofiltration devices [13]. Conversely, CytoSorb® does not have the capacity 
to remove endotoxins, which was suggested to be its main disadvantage [13]. 
The adsorbing capacity of the CytoSorb® cartridge is asserted concentration 
dependent, thus, the higher the cytokine level in the blood the faster they will 
be adsorbed. Conversely, if the cytokines concentration is low there will be 
no complete elimination of cytokines from the blood. This intends to prevent 
overtreatment [16]. 
B0003 – What is the phase of development and implementation of ECAT? 
The principle of filtering and adsorbing molecules from the blood is not new 
and has been used in haemodialysis machines for a few decades. The first 
studies proposing the idea of extracorporeal removal of pro-inflammatory 
cytokines for the treatment of sepsis were published around the year of 1995. 
However, similarly, as to other extracorporeal blood purification techniques, 
haemadsorption devices are in an early stage of implementation, with only 
limited clinical data being available to date [13, 15].  
Only two randomised controlled trials have been completed until today; re-
sults are published for only one of them (see synthesis of results). The tech-
nology is in an experimental stage and its use is not established in clinical 
practice. An international patient registry has been created in order to report 
cases of compassionate use and to evaluate safety profiles outside of random-
ised controlled trials (RCT) [17]. 
While awaiting the results of the clinical trials, CytoSorbents launched the 
next generation of the haemadsorption device ‘CytoSorb®-XL in September 
2016 presenting initial results from in vitro studies [18]. In comparison to the 
original device CytoSorb®, CytoSorb®-XL has the additional capacity to re-
move endotoxin from the blood.  
In a press release the manufacturer claims a potential addressable market in 
the US and in Europe of more than $1.5 billion for CytoSorb® for its use dur-
ing CPB surgery alone. Overall, the manufacturer claims a $20 billion mar-
ket potential of CytoSorb® for critical care applications worldwide2. 
                                                             
2 http://www.prnewswire.com/news-releases/cytosorbents-announces-fda-
approval-to-commence-initial-us-cardiac-surgery-study-300028992.html 
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Administration, Investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers ECAT and in what context and level of care  
is it provided? 
B0008 – What kind of special premises are needed to use ECAT? 
B0009 – What supplies are needed to use the technology? 
There are three modes of application of the CytoSorb® technology: as stand-
alone therapy, in combination with CRRT and during cardiopulmonary by-
pass procedures.  
The setup of the technology and the application procedure is claimed to be 
simple with only little training efforts required. CytoSorb® has standard di-
alysis connectors that are compatible with the most commonly used haemo-
dialysis machines, CRRT devices and heart-lung machines. The technology 
is used in intensive care units and in operating rooms during cardiac surgery.  
Personnel that acquired appropriate training in the management of extra-
corporeal therapies can administer CytoSorb®. A physician should direct the 
use of CytoSorb® and should have received training in the correct use of the 
technology [19].  
Patients need to be effectively anticoagulated at the start of the treatment with 
heparin or citrate. The aPTT (activated partial thromboplastin time) and ACT 
(activated clotting time) when using heparin anticoagulation, or ionized cal-
cium for citrate anticoagulation should be checked regularly during treatment 
to ensure adequate anticoagulation [16].  
Before the start of the treatment, the supply tube system must be airlessly 
prefilled with a minimum of two litres sterile isotonic saline solution. Pres-
sure monitoring of the bloodline between the device and the blood pump is 
recommended throughout the treatment [19]. 
The patient blood is continuously recirculated between the absorption device 
and the patient. The usage of one cartridge should not exceed 24 hours; reuse 
might lead to secondary infections or clotting. The absorber can be replaced 
daily for a maximum of seven days of continuous ECAT treatment. The typ-
ical treatment duration for sepsis patients is 48 hours to 72 hours [16]. The 
preventive use of ECAT during CPB surgery lasts as long as the heart-lung 
machine is connected. The use of CytoSorb® during CPB surgery is recom-
mended for a CPB duration of more than >120 min [16].  
Materials required for the setup of the technology are the sterile CytoSorb® 
cartridge, bloodlines that are compatible with the used blood pump system, 
plastic scissor clamps, isotonic saline solution, and female Luer connectors 
to connect with the CytoSorb® blood ports. The roller blood pump should be 
capable of delivering up to 400 mL/min blood flow rate. The typical flow rate 
is 150- 500 ml/min [19].  
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Regulatory & reimbursement status  
A0020 – For which indications have ECAT devices received  
marketing authorisation or CE marking? 
In Europe, CytoSorb® received its CE mark in 2011 as the first haemadsorp-
tion device indicated for the treatment of conditions with excessive cytokine 
levels.  
In the US, the manufacturer CytoSorbents, Inc currently seeks market ap-
proval at the Food and Drug Administration (FDA). A safety and feasibility 
trial on CytoSorb® use during complex cardiac surgery was initiated in 2015 
under the Investigational Device Exemption (IDE)3 (NCT02566525). Accord-
ing to the manufacturers, this first pilot study was recently completed; the 
results are still pending.  
Excessive cytokine levels occur in several conditions.  
The two main indications for the use of CytoSorb® are  
  the therapeutic treatment of SIRS and sepsis 
 the preventive intraoperative or post-operative use of CytoSorb®  
during cardiac surgery to prevent SIRS.  
These two fields of application are also the focus of the majority of ongoing 
trials on the clinical use of CytoSorb®.  
A0021 – What is the reimbursement status of ECAT? 
At present, ECAT is not included in the Austrian benefit catalogue.  
In Germany, the technology has been added to the German OPS catalogue 
(Operationen und Prozedurenschlüssel) and the InEK (Entgeltsystem im 
Krankenhaus) in November 2016, the addition is effective with 01.01.2017. 
Since 2017, German hospitals can directly negotiate an individual reimburse-
ment for the CytoSorb® therapy. To the knowledge of the authors, Germany 
is the first European country to reimburse CytoSorb® therapy.  
There are no official list prices of CytoSorb® treatment available in Germany 
or Austria. In a recent Medtech innovation briefing on CytoSorb® published 
by the National Institute for Health and Care Excellence (NICE) the UK list 
price of one single use CytoSorb® device is 920£ (1066.70 EUR4), excluding 
VAT (value added tax) [20]. As adjunctive treatment, the costs of the tech-
nology would be an addition to the costs of standard care.  
 
                                                             
3 http://cytosorb-therapy.com/pressarticle/cytosorbents-submits-ide-application-
fda-u-s-cytosorb-cardiac-surgery-trial/ 
4 http://www.xe.com/currencyconverter; official exchange rates, 24/01/2017 
CytoSorb®:  
EU CE-Mark seit 2011 
USA: keine Zulassung, 
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nicht veröffentlicht 
2 Indikationsbereiche:  
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derzeit nur in 
Deutschland (seit 2017) 
rückerstattet 
UK-Preis:  
920£/1.067 EUR 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is ECAT used? 
Currently, several indications are being investigated for the use of ECAT. The 
common denominator of these conditions is an excessive level of cytokines in 
the blood. The main indications and primary focus of ongoing research are 
the treatment and prevention of SIRS and sepsis, as afore described in A0020.  
Case reports on first clinical applications of CytoSorb® in other hyper-in-
flammatory conditions have been published or presented at conferences, and 
include the following (not subject of this assessment): 
 Polytrauma and rhabdomyolysis 
 Serious burn injury 
 Severe acute pancreatitis 
 Various types of liver failure 
 Severe cardiogenic shock 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
The focus of this assessment is the application of ECAT devices in patients 
with sepsis and septic shock. Furthermore, we assessed its effectiveness as a 
preventive intervention for patients undergoing cardiopulmonary bypass sur-
gery who risk developing SIRS.  
Sepsis, septic shock and SIRS are closely linked conditions that are associated 
with a dysfunctional immune response.  
Despite the therapeutic advances of recent years, the mortality and morbidity 
of sepsis and septic shock remained high. Even with optimal treatment, the 
mortality of sepsis and septic shock is estimated to be more than 10% and 
more than 40% respectively [1].  
The definitions of sepsis and septic shock have evolved since the 1990s. In 
2016, new international consensus definitions (Sepsis-3 guidelines) on sepsis 
and septic shock were published by the Society of Critical Care Medicine 
(SCCM) and the European Society of Intensive Care Medicine (ESICM) and 
endorsed by several national and international societies [1]. These consensus 
definitions were also considered for the purpose of this assessment. The Sep-
sis-3 definition has two grades: sepsis and septic shock. Notably, one key re-
commendation from the new definitions is that SIRS is no longer included 
in the definition of sepsis, due to the lacking sensitivity and specificity of the 
criteria to detect patients with sepsis.  
Definition Sepsis 
Sepsis is a clinical syndrome that exists on a continuum of severity ranging 
from an infection and bacteraemia (bacteria in the blood) to severe multi 
organ dysfunction with septic shock [3]. According to the SCCM/ESICM 
task force, sepsis is defined as ‘life-threatening organ dysfunction caused by 
a dysregulated host response to infection’ [1].  
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Sepsis may stem from an infection of any part of the body, most commonly 
from the lungs, intestine or urinary tract. In an estimated 30% of sepsis cases 
the causative infection cannot be identified and can only be assumed by the 
clinical presentation of the patient [1, 21]. Patients with suspected sepsis pre-
sent themselves often with tachycardia, fever, hypotension and leucocytosis 
[21].  
Clinically, the organ dysfunction can be identified by an acute change in the 
SOFA score (Sepsis-related Organ Failure Assessment) by two or more points, 
which is associated with an in-hospital mortality greater than 10% [1]. 
The 2016 SCCM/ESICM consensus definitions noted that the term severe sep-
sis is redundant under the present terminology of sepsis and septic shock [1]. 
Originally, severe sepsis referred to sepsis with organ dysfunction or sepsis 
with tissue hypoperfusion, which today is included in the definitions of sep-
tic shock [1, 22].  
Table 4-1: Sepsis Related Organ Failure Assessment Score, adapted from  
Vincent et al. 1996 [23] 
SOFA score 1 2 3 4 
Respiration 
PaO2/FiO2, mmHg 
< 400 < 300 < 200 < 100 
with respiratory support 
Coagulation 
Platelets x 10³/mm³ 
< 150 < 100 < 50 < 20 
Liver 
Bilirubin, mg/dl  
1.2-1.9 2.0-5.9 6.0-11.9 >12.0 
Cardiovascular 
Hypotension 
MAP  
< 70 mmHg 
Dopamine ≤ 5 or 
dobutamine  
(any dose)a 
Dopamine > 5 or 
epinephrine ≤ 0.1 or 
norepinephrine ≤ 0.1 
Dopamine > 15 or 
epinephrine > 0.1 or 
norepinephrine > 0.i 
Central nervous system 
Glasgow Coma Score 
13-14 10-12 6-9 < 6 
Renal 
Creatinine, mg/dl or  
urine output ml/d 
1.2-1.9 2.0-3.4 3.5-4.9 or < 500 ml/d >5.0 or < 200ml/d 
a Adrenergic agents administered for at least 1h (doses given are in µg/kg min) 
 
Definition septic shock 
Septic shock is an extensive vasodilatory reaction that leads to hypoperfusion 
of the body [1, 21]. Due to the vasodilation of the arteries and capillaries, the 
blood is pooled in the periphery of the circulatory system causing severe hy-
potension.  
The SCCM/ESICM guidelines define septic shock as a subset of sepsis with 
a substantially greater risk of mortality due to a particularly profound system-
ic response. Clinically, the status of septic shock is distinguished from sepsis 
by the persistence of hypotension that requires vasopressor therapy to main-
tain a mean arterial pressure of 65mmHG and serum lactate level greater than 
2mmol/l (18mg/dL) in absence of hypovolemia [1].  
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Definition SIRS 
The systemic inflammatory response syndrome (SIRS) is a clinical syndrome 
of a dysregulated inflammatory response that may or may not be accompanied 
by an infection.  
SIRS is clinically defined by having at least two of the following criteria:  
 Temperature > 38°C or < 36°C 
 Heart rate of more than 90 beats per minute 
 Respiratory rate more than 20 beats per minute or  
PaCO2 of less than 32mmHg 
 Abnormal white blood cell count (> 12,000/mm³ or < 4,000/mmm³) 
[1, 22] 
Until 2016, the international consensus definition for severe sepsis required 
suspected or proven infection, organ failure, and clinical signs that meet two 
or more criteria for SIRS [3]. However, this definition has fallen out of fa-
vour because many patients who fulfilled the criteria for SIRS did not devel-
op severe sepsis [1, 21]. Furthermore, research showed that its predictive ca-
pacity on mortality was poor compared with other scoring tools such as the 
SOFA score [1]. 
The aetiology of SIRS is broad and, apart from infectious causes, comprises 
non-infectious conditions such as autoimmune disorders, pancreatitis, vas-
culitis, thromboembolism, burns, or surgery.  
Independent from the aetiology of SIRS, the underlying pathophysiologic 
mechanisms that trigger the excessive immune response are similar. Nonspe-
cific insults that can arise from chemical, traumatic or infectious stimuli lead 
to the natural immune response of inflammation. An inflammatory cascade 
is triggered, involving multiple humoral and cellular responses that lead to the 
release and production of cytokines [8].  
A0003 – What are the known risk factors to develop sepsis or SIRS? 
Several risk factors are associated with developing sepsis [21]. The incidence 
of sepsis increases disproportionally in patients above the age of 65 years, 
and advanced age is considered a predictor of sepsis-related mortality. Older 
patients die sooner during hospitalisation and elderly sepsis- survivors show 
worse long-term outcomes compared to younger survivors [24]. Further risk 
factors include immunosuppression, and disease conditions, such as diabe-
tes, cancer, community-acquired pneumonia, and patients with trauma and 
major surgical procedures [21]. Moreover, genetic factors that may alter the 
innate immune response and increase susceptibility to specific microorgan-
isms have been identified that seem to contribute to a higher risk of develop-
ing sepsis [25].  
Due to the high rate of nosocomial infectious in intensive care units (ICU) 
admission to an ICU increases the risk of developing sepsis. Similarly, pre-
vious hospitalisation increases the risk of developing sepsis by three-fold in 
the 90 days following discharge [26]. Patients who were admitted for infec-
tion-related conditions, in particularly for infections with bacterium Clostrid-
ium difficile, are at greatest risk.  
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Similarly as to sepsis, the risk of developing SIRS is higher for patients with 
advanced age, immunosuppression, and underlying conditions that affect the 
immune system. One particular risk factor relevant for this assessment is the 
risk of developing SIRS after cardiac surgery. The use of the heart-lung ma-
chine during surgery provokes a systemic inflammatory response, triggered 
by contact activation of blood by artificial surfaces. In most cases, this im-
mune response is transient and self-terminating at the end of CBP. However, 
some patients (2-10%) develop SIRS with major organ dysfunction and poor 
outcomes [27, 28].  
A0004 What is the natural course of sepsis, septic shock and SIRS? 
Left untreated sepsis and septic shock can have a lethal outcome. Even with 
the optimal therapy, the mortality of sepsis is high with estimated rates rang-
ing from 10 to 52% [21]. Mortality is lower in younger patients without co-
morbidities.  
After hospital discharge, patients can have a higher risk of further sepsis and 
re-admission to the hospital. The long-term prognosis is an increased risk of 
death following hospital discharge, with most deaths occurring in the first 
six months [29]. Furthermore, sepsis survivors reported limitations on their 
quality of life in terms of functional restrictions, such as sustained restrictions 
in neurocognitive functions, post-traumatic distress disorder or depression. 
This condition is described as critical illness polyneuropathy (CIP) or criti-
cal illness myopathy (CIM) [3].  
The natural cause and prognosis of SIRS depends on the underlying condi-
tion and the aetiological source of SIRS.  
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What are the symptoms and the burden of disease  
or health condition for the patient? 
Patients with suspected sepsis or SIRS present themselves with a combina-
tion of several non-specific symptoms: hypotension, fever or temperature be-
low 36° C, a high respiratory rate, an accelerated heart rate (> 90 beats/min), 
an altered mental status with symptoms of acute confusion, and signs of hy-
poperfusion. Additionally, they may show symptoms that are specific to the 
infectious origin, for example, coughing and dyspnoea in cases of pneumonia 
[21]. As the disease progresses patients may develop symptoms of shock with 
signs of severe hypoperfusion, such as absent bowel sounds (Ileus) and cya-
nosis [8]. 
A0006 – What are the consequences of sepsis for the society? 
As a consequence of the demographic changes with advancing age, increased 
use of immunosuppression and rising occurrence of multi-resistant infections 
the incidence of sepsis is increasing in the past 20 years. This increase was 
also associated with better early detection strategies and growing awareness of 
the disease, yet it is anticipated that the sepsis incidence will keep rising in 
the future [21].  
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In Germany, the direct medical costs for the treatment of septic patients in 
an intensive care unit were estimated to be 1.77 billion Euro annually, which 
represents 30% of the total intensive care budgets in Germany [3]. The UK 
National Health Service (NHS) annual reference cost for sepsis in 2014/2015 
were £6400 to £9673 per patient with sepsis [20]. 
For Austria, the latest accessible information on costs of sepsis stem from 
2002; the total direct costs were calculated to be between 192 million Euros 
to 272 million Euros annually [30]. Direct costs represent only 20-30% of the 
total costs of sepsis, whereby the other 70% arise from indirect costs of pro-
ductivity loss [31].  
 
Current clinical management of the disease or health condition 
A0024 – How is sepsis and SIRS currently diagnosed according  
to published guidelines and in practice? 
A combination of clinical parameters, laboratory, microbiologic and haemo-
dynamic data leads to the diagnosis of sepsis. Often, the diagnosis is made 
retrospectively. Suspected sepsis patients are initially diagnosed at the bed-
side upon clinical presentation, and the tentative diagnosis is later confirmed 
when laboratory or microbiological data returns. The identification of the un-
derlying infection is highly supportive of the diagnosis of sepsis, however, not 
always possible [21]. 
Patients with suspected infection likely to develop sepsis can be identified by 
applying the qSOFA score (quickSOFA), a quick and simplified scoring tool 
developed by the Sepsis-3 guideline task force to facilitate bedside screening 
of sepsis inside and outside from hospital settings. The qSOFA criteria con-
sist of a respiratory rate of more than 22/min, an altered mental state with a 
GCS < 15 and a systolic blood pressure of less than 100mgHg [1]. If the 
qSOFA score is positive, organ dysfunction should be assessed according to 
the full SOFA score variables.  
Laboratory signs of sepsis are unspecific, but can be associated and eviden-
tial for the underlying organ dysfunction or infection. Relevant laboratory pa-
rameters include leukocytosis or leucopenia, white blood cell count with more 
than 10% immature progenitor cells, hyperglycaemia in the absence of dia-
betes, elevated CRP levels, arterial hypoxemia, acute oliguria, creatinine in-
crease, coagulation abnormalities, thrombocytopenia, and increased levels of 
bilirubin and lactate [21]. Figure 4-1 provides an overview of the diagnostic 
algorithm to identify patients with sepsis, developed by the sepsis-3 taskforce.  
The diagnostic criteria for SIRS were described above. If patients present 
themselves with at least two out of the four parameters, they meet the crite-
ria for the condition of SIRS [1].  
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Figure 4-1: Clinical criteria to identify patients with sepsis and septic shock, developed by the SCCM/ESICM 
taskforce, from Singer et al. 2016 [1] 
A0025 – How is sepsis and SIRS currently managed according to 
published guidelines and in practice? 
The two main therapeutic priorities for patients with sepsis include early iden-
tification of the infectious origin and early initiation of supportive care to en-
sure haemodynamic stabilisation [32].  
The Surviving Sepsis Campaign International Guidelines for the Management of 
severe sepsis and septic shock recommended a care bundle of specific interven-
tions to be completed within the first three and first six hours of the manage-
ment of a septic patient (see Figure 4-2) [33]. 
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Control of septic focus 
The early identification of the primary site of infection is essential, and the 
only causal therapeutic measure in the treatment of sepsis to date. Moreover, 
the identification of an infection is needed to distinguish sepsis from SIRS 
[32].  
Early and adequate antibiotic treatment is essential for the treatment of sep-
sis (‘hit early and hit hard-strategy’). Intravenous antibiotic therapy should be 
started within the first hours, and after obtaining blood cultures [3]. If the 
pathogen is not obvious and unknown, the initial antibiotic therapy should 
be a combination of broad-spectrum antibiotics that are effective for gram-
negative and gram-positive bacteria, such as third or fourth generation ceph-
alosporin or carbapenem [34]. Furthermore, potential infective sources, i.e. 
devices and vascular access lines, should be controlled and if possible, re-
moved.  
Supportive therapy 
The second priority in patients with sepsis and septic shock is to achieve 
haemodynamic stabilisation.  
Initial therapeutic priorities include securing of the airway, ensuring adequate 
oxygenation of the blood, and treating hypoperfusion and hypotension. Some 
patients require mechanical ventilation and intubation [32].  
The most recent international guideline (2016) commissioned by the Surviv-
ing Sepsis Campaign recommends an initial volume therapy with crystalloid 
fluids of minimum 30mL/kg to be given within the first 3 hours (strong rec-
ommendation, low quality of evidence) [2]. Further fluid administration should 
be guided by frequent reassessment of the haemodynamic status (best practise 
statement). The initial target mean arterial pressure (MAP) should be 65mm 
HG in patients in shock requiring vasopressors (strong recommendation, mod-
erate quality of evidence).  
The Surviving Sepsis Campaign Guidelines provides detailed recommenda-
tions for the optimal fluid therapy, vasopressor therapy, airway and ventila-
tion management and further adjunctive therapeutic options, such as insulin 
therapy [2]. The guidelines do not recommend the use of blood purification 
therapies including ECAT, since the underlying evidence does not suffice to 
provide a recommendation [2]. 
The latest German sepsis guideline was issued by the AWMF and Deutsche 
Sepsis Gesellschaft in 2010 [34]. The level of evidence for the optimal man-
agement of sepsis is constantly updated. Many therapeutic options only have 
weak recommendations due to a low quality of evidence and trials to deter-
mine their effectiveness are currently ongoing [2, 35].  
Since SIRS is a syndrome rather than a disease, the treatment and manage-
ment of a patient with SIRS depends on the inciting cause. Symptomatic 
management and stabilisation of the patient is essential and similar to the 
supportive management of sepsis [8].  
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Target population 
A0007 – What is the target population in this assessment? 
Two target populations arise from the main fields of application: 
 Patients with sepsis and septic shock 
The therapeutic use of CytoSorb® in patients with sepsis is indicated 
in patients that cannot be clinically stabilised with standard medical 
treatment, have clinical signs of hyperinflammation, develop organ 
dysfunction, or have systemic markers of infection.  
The target patient groups include postsurgical patients with on setting 
sepsis, acute kidney failure, or patients with therapy refractory septic 
shock. Furthermore, patients with impaired immune competence due 
to a chronic disease (chronic liver disease, dialysis patients), and elder-
ly patients belong to the potential patient population.  
 Development of SIRS during or following cardiac surgery with CPB 
The preventive use of CytoSorb® during cardiac surgery with CPB is 
proposed for patients with the following risk factors:  
 Age >75 
 Preoperative status with endocarditis, cardiac failure, leukocytosis 
or organ dysfunctions 
 High-risk procedures: Combination of procedures (valve repair and 
cardiac bypass graft), re-operation, aortic surgery with hypothermic 
arrest, left ventricular assist device (LVAD) implantation 
Furthermore, its use is suggested for patients with intraoperative development 
of SIRS, prolongation of the anticipated CPB time, or complication where 
postoperative onset of SIRS is likely.  
A0023 – How many people belong to the target population?  
A0011 – How much is ECAT utilised? 
For Austria, the estimated number of patients with ‘severe’ sepsis ranges from 
6,700 to 9,500 per year [30]. Another study estimated 54-116 sepsis cases per 
year per 100,000 inhabitants. These data stem from 2002 and 2004 [31], how-
ever, since the overall number of sepsis patients is increasing, it can be as-
sumed that this number is still equally high or higher today.  
Data on the numbers of cardiac procedure requiring CPB to estimate the use 
of ECAT during cardio-pulmonary bypass surgery were not available for Aus-
tria. Several surgical procedures apply CPB, such as coronary artery bypass 
graft surgery, valve replacement, heart or lung transplantation, LVAD proce-
dures for heart failure and operations on the aortic arch.  
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5 Clinical effectiveness 
5.1 Outcomes 
Within the scope of both applications of ECAT as preventive and therapeutic 
treatment, the following outcomes were defined as crucial to derive a recommen-
dation: 
 Improved survival 
 Improved clinical outcomes: organ functions 
(MODS or SOFA score) 
 Days in ICU 
 Days of hospitalization 
Since sepsis is a life-threatening disease, the ultimate aim of the treatment with 
ECAT is to improve mortality. Improved survival and improved organ function, 
measured with the SOFA score were consequently regarded as crucial for a rec-
ommendation of CytoSorb® as supportive treatment of sepsis. The SOFA score 
was endorsed by the 2016 sepsis-3 guideline as most sensitive tool to predict mor-
tality and poor outcomes in patients with suspected sepsis. Furthermore, it was 
suggested to be used as entry criterion for clinical trials [1]. It is applied by many 
ongoing trials on sepsis and SIRS.  
The preventive treatment with ECAT during cardiac surgery aims to reduce the 
number of sustained post-surgical SIRS. In this regard, while survival is equally 
important, it is not as relevant, since only 10% (generously estimated) of patients 
develop sustained SIRS during CPB. Consequently, the most crucial patient rel-
evant outcomes were improved clinical outcomes, such as improved organ func-
tions, and a decrease of days spent in the ICU and total days of hospitalization. 
This is in line with outcome measures recommended for clinical trials on extra-
corporeal blood treatment in SIRS and sepsis [36] 
Additionally, the following parameters were considered relevant to assess 
effectiveness of the therapy:  
 Ventilator free days 
 Decrease in dose of vasopressor drugs and catecholamines 
 Reduction of cytokine levels in the blood 
The claimed benefit of ECAT is the reduction of cytokine levels in the blood to 
restore a balanced immune response. Accordingly, in order to assess the efficacy 
of the technology to remove cytokines, the reduction in the cytokine concentra-
tion was also analysed. However, there is no clear evidence whether and how the 
general reduction of cytokines in the blood directly influences patient outcomes 
in sepsis and SIRS. Thus, while qualitatively described in the results part of this 
assessment, this outcome was not designated as crucial for the recommendation.  
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5.2 Included studies 
To evaluate efficacy-related outcomes, we considered all published studies that 
included a comparison group.  
In total, two studies were included to analyse the clinical effectiveness of ECAT 
[37, 38], of which only one met the initial inclusion criteria. The studies com-
prised one randomised controlled trial published in 2016 (n=37, 19 receiving 
ECAT), and one retrospective case series from 2014 (n=40, 20 receiving ECAT).  
Both studies evaluated the preventive use of CytoSorb® during CPB surgery. In-
clusion criteria for the RCT were elective cardiac surgery with an expected CPB 
duration of more than 120 minutes. The case series investigated the use of Cyto-
Sorb® in CPB surgery and hypothermic arrest with antegrad cerebral perfusion, 
specifically. 
We could not identify data from any randomised or non-randomised controlled 
trial assessing the effectiveness of CytoSorb® in patients with sepsis or septic 
shock.  
Patient characteristics were missing for one of the two studies [38]. The mean age 
of patients in the RCT was 67 years. 29.7% of the patients in the intervention 
group were female, as compared to 22.2% in the control group. The follow-up of 
the RCT was 30 days, the case series only had a follow-up of four days post-sur-
gery [37, 38].  
The loss to follow-up was only reported by Bernardi et al. (RCT), with a percent-
age of 30% loss to follow-up [37]. Both studies shared their primary outcome 
measure, a decrease the cytokine IL-6.  
Study characteristics and results of included studies are displayed in Table A-1 
and Table A-2 and in the evidence profile in Table 7-1. 
 
 
5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of ECAT on mortality? 
Preventive use of CytoSorb® to reduce SIRS during elective CPB surgery 
Bernardi et al. (RCT) assessed 30 day mortality as secondary outcome measure 
in 37 patients [37]. One out of 19 patients in the intervention group died on the 
22nd postoperative day. All 18 patients in the control group survived the 30 days.  
Born et al. did not report on improvements in mortality [38]. 
Therapeutic use of CytoSorb® in patients with sepsis or septic shock 
None of the studies reported on sepsis mortality.  
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Morbidity 
D0005 – How does ECAT affect symptoms and findings (severity, frequency) 
of SIRS or sepsis? 
To answer this research question the crucial outcome ‘improved clinical outcomes 
of organ functions’ was used and evaluated by a change in the MODS or in the 
SOFA score.  
Neither SOFA score, nor MODS score, nor any other score measure to assess or-
gan failure was reported by the two studies. 
Regading the surrogate outcome of a change in the cytokine concentration in the 
blood, both studies assessed changes in the serum level of the cytokine IL-6. Born 
et al. reported a siginifact decrease in IL-6 levels until the forth post-operative 
day [38]. Conversely, this decrease was not found in Bernardi et al., who found 
no significant differences between both groups, measured until the fifth post-
operative day [39].  
D0006 – How does the technology affect progression (or recurrence) 
ofsepsis or SIRS? 
In order to answer this research question, lengths of ICU stay, days of hospitali-
zation, mechanical ventilation and need of catecholamine medication were ap-
plied as indicators for disease progression.  
Bernardi et al. (RCT) found no significant difference in the length of stay in in-
tensive care units between the intervention group (2.3 days, +/- 2) and the control 
group (2.4 days, +/- 1.9) [37].  
Differences in the total length of hospitalisation follow up of the patients after 
hospital discharge and re-admission to hospital were not assessed by any of the 
studies.  
Bernardi et al. (RCT) reported no significant difference in the days of mechani-
cal ventilation (p=0.19), and no difference in the need of catecholamines (p value 
not claculated) in patients with SIRS [39].  
 
Function 
D0011 – What is the effect of the technology on patients’ body functions? 
None of the studies reported results on the patient’s body functions. 
 
Health-related quality of life 
D0012 – What is the effect of ECAT on generic health-related quality of life? 
D0013 – What is the effect of ECAT on disease-specific quality of life? 
None of the studies reported results on the health-related quality of life, nor on 
the disease-specific quality of life.  
 
Patient satisfaction 
D0017 – Were patients satisfied with ECAT? 
None of the studies assessed patient satisfaction.  
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6 Safety 
6.1 Outcomes 
As any extracorporeal circuit, the treatment with CytoSorb® can lead to device 
and procedure-related side effects. One potential side effect of extracorpore-
al circuits is clotting of the blood in the circuit, which can either block the 
circuit and oxygenator or send a blood clot into the patient, which subsequent-
ly can cause an embolic event. Furthermore, leakage of the device and dis-
connection of the bloodline can cause sudden excessive blood loss.  
The instructions for use of CytoSorb® specifically advise the user to control the 
pressure of the extracorporeal circuit and tightly monitor anticoagulation, to 
reduce the risk of blot clotting [19]. Air entering the bloodlines and the cir-
cuit can result in serious injury and even death, as this could cause air em-
bolism.  
The manufacturers further warn that in rare cases hypersensitivity reactions 
may occur during the treatment. In the event of a hypersensitivity reaction, 
the physician would have to decide whether to return the blood to the pa-
tient [19].  
Additional potential side effects are hypotension, change of the body temper-
ature, muscle cramping, headache, nausea, vomiting, fever and pruritus.  
The following outcomes were defined as crucial to derive a recommendation: 
 Perioperative (serious) adverse events and complications  
 Postoperative (serious) adverse events and complications 
In accordance with the European Commission guidelines for medical devices 
on serious adverse event reporting, the following definitions were applied5:  
Adverse Event (AE) is any untoward medical occurrence, unintended disease 
or injury or any untoward clinical signs (including an abnormal laboratory 
finding) in subjects, users or other persons whether or not related to the in-
vestigational medical device. This includes events related to the investigation-
al device or related to the procedures involved (any procedure in the clinical 
investigation plan).  
Serious Adverse Event (SAE) is an adverse event that led i) to death, ii) to a 
serious deterioration in health of the subject that either resulted in a life-
threatening illness or injury, iii) a permanent impairment of a body structure 
or a body function, iv) in-patient hospitalisation or prolongation of existing 
hospitalisation, v) medical or surgical intervention to prevent life threaten-
ing illness or injury. 
Serious Adverse Device Effect (SADE) is an adverse event related to the use 
of a medical device that has resulted in any of the consequences characteris-
tic of a serious adverse event.  
                                                             
5 http://ec.europa.eu/consumers/sectors/medical-
devices/files/meddev/2_7_3_en.pdf  
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6.2 Included Studies 
In order to assess safety-related outcomes, we accepted all published evidence 
with more than 10 patients.  
We could not identify any randomised controlled trial or non-randomised trial 
that specifically described safety outcomes, or reported adverse events as their 
primary or secondary outcomes.  
Three studies were included to analyse the safety of ECAT [31-33]. The stud-
ies comprised one randomised controlled trial published in 2016 (n=37, 19 
receiving ECAT) and two retrospective case series from 2016 (n=16) and 2014 
(n=40, 20 receiving ECAT) respectively.  
One study, a retrospective case series including 16 patients, assessed the use 
of CytoSorb® as an additive therapeutic option in the treatment of post-car-
diopulmonary bypass SIRS [40]. The two other studies assessed the preven-
tive use of CytoSorb® during cardiopulmonary bypass surgery to reduce the 
occurrence of SIRS post-surgery.  
Bernardi et al. (RCT) and Born et al. (case-series) included patients undergo-
ing cardiac surgery with CPB, as afore described [37, 38]. Conversely, Träger 
et al. (case-series) included patients post- CPB surgery that developed post-
CPB SIRS over the course of the first postoperative 24-hours [40]. The mean 
age in the studies was around 70 years, 71 in Träger et al. and 67 in Bernardi 
et al. The latter two studies included similar follow-up, with 28 and 30 days 
following surgery. Exclusion criteria are only reported by Bernardi et al. and 
can be found in the data extraction tables in the Appendix.  
We could not identify any study that reported data on the safety of CytoSorb® 
as therapeutic option in the treatment of sepsis or septic shock.  
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table 7-1. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is ECAT in comparison to the comparator(s)? 
There is no direct comparator to ECAT.  
None of the studies reported adverse or serious adverse events for the use of 
CytoSorb® either during CPB surgery or post-operative [37, 38, 40]. In total, 
the technology was used in 55 patients. Furthermore, no adverse device ef-
fects were described. 
C0002 – Are the harms related to dosage or frequency of applying ECAT? 
None of the studies reported results to answer this question.  
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C0004 – How does the frequency or severity  
of harms change over time or in different settings? 
None of the studies reported results on how frequency and severity  
of potential harms change over time.  
C0005 – What are the susceptible patient groups  
that are more likely to be harmed by the use of ECAT? 
No evidence was found to answer this research question.  
C0007 – Is ECAT associated with user-dependent harms? 
No evidence was found to answer this research question.  
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of ECAT? 
No evidence was found to answer this research question.  
 
keine Evidenz 
keine Evidenz 
keine Evidenz 
keine Evidenz 
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) Scheme [5] for each 
endpoint individually. Each study was rated by two independent researchers 
(KH, CW). In case of disagreement a third researcher was involved to solve 
the difference. A more detailed list of criteria applied can be found in the re-
commendations of the GRADE Working Group [5].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
Overall, the strength of evidence for the effectiveness and safety of ECAT is 
very low.  
 
Qualität der Evidenz 
nach GRADE 
Stärke der Evidenz:  
sehr niedrig  
  
E
xtraco
rp
o
real cyto
kin
e h
aem
ad
so
rp
tio
n
 th
erap
y 
4
2 
LB
I-H
T
A
| 20
17 
Table 7-1: Evidence profile: efficacy and safety of extracorporeal haemadsorption therapy  
No of 
studies/patients 
Study  
Design Estimate of effect Study limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength of 
evidence 
Efficacy 
28-day mortality 
1/37 RCT Int: 1/19 vs Co: 0/18  Serious limitations (-1)1 Only one study direct Imprecise data (-1)2 low 
1/16 Case series 6/16 Serious limitations (-1)3 Only one study direct - Very low 
Improved organ function (SOFA score) 
1/37 RCT NR 0 0 0 0  
Days in ICU 
1/37 RCT Int: 2.3 (+/- 2) Co:  
2.4 (+/-1) p= 0.87 
Serious limitations (-1)1 Only one study Direct Imprecise data (-1)2 low 
Days of hospitalisation  
No data 
Safety 
Treatment-related mortality in % (Int vs Co)* 
No data 
Serious AE 
None reported 
1 Unclear allocation concealment, outcome assessors not blinded, 30% loss to follow-up 
2 Low power of the study (few patients) 
3 No control group 
NR = not reported  
* unclear if 28-day mortality is treatment related 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
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8 Discussion 
ECAT is an emerging technology with very limited clinical evidence availa-
ble to date. We could retrieve evidence from three studies, one technical fea-
sibility RCT and two retrospective observational studies; however only one 
study met our initial inclusion criteria for both efficacy and safety. In total, 
93 patients were enrolled in the studies, of which 55 patients were treated 
with CytoSorb®. We did not limit our search to a specific study design, lan-
guage or period and included all studies that provided clinical data of more 
than five patients.  
In addition to the included studies, we could identify 17 case reports as pre-
sented in Appendix A, Table A–5. The case reports, all published between 
2013 and 2016, present examples of first-time use of CytoSorb® in several dif-
ferent conditions reflecting the early stage of the technology in clinical use. 
Case reports represent a very low level of evidence and due to the lacking con-
trol and comparison groups, evidently, no conclusions for the clinical effec-
tiveness of the technology can be drawn. Furthermore, there is large hetero-
geneity in between the assessed conditions and patient groups of the case re-
ports on CytoSorb®. Additionally, we found several unpublished studies where 
only abstracts or conference posters were available. A recent technology brief-
ing conducted by NICE, and presented in Appendix A Table A-6 provides 
an overview of this preliminary study material.  
In terms of clinical effectiveness, we could only identify two controlled stud-
ies to investigate the potential effects of CytoSorb® therapy during CPB sur-
gery, one RCT and one retrospective case series [37, 38]. While both studies 
presented results on the same indication and intervention, the comparability 
of the patient groups could not be fully assessed, since only Bernardi et al. 
(RCT) reported patient characteristics. Both studies assessed a change in the 
level of cytokines as primary outcome measures, with IL-6 as principal inves-
tigated cytokine. Born et al. suggested a significant reduction of the level of 
IL-6 in the blood; Bernardi et al. reported no significant differences in IL-6 
levels between the control and the intervention group. The relevance of this 
outcome regarding the clinical benefit for patients is unclear [41, 42].  
Patient-relevant outcomes, such as data on 30-day mortality, lengths of ICU 
stay and days of mechanical intervention, were provided by Bernardi et al., 
yet only as secondary outcome measure [37]. In this regard, no significant dif-
ferences between the intervention group and the study group were found. 
Both studies failed to report changes in the SOFA or other scores assessing 
organ dysfunction in sepsis or SIRS [1]. 
There was no evidence on the effect of ECAT in patients with sepsis and septic 
shock. Moreover, no data on CytoSorb® use in patients with sepsis was avail-
able, other than from case reports. One single RCT comparing ECAT with 
standard of care was identified, however, it is only available in abstract form 
[43, 44], and thus, data and quality of the study could not be assessed. This 
preliminary study material has been described in the NICE briefing men-
tioned above and depicted in Table A-6 [20].  
Sepsis and septic shock represents the principal and original indication for 
CytoSorb® use. The lacking data on effectiveness for this indication underlines 
the imperative need for adequate efficacy studies prior to its introduction to 
everyday clinical practice [41].  
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As regards to safety of the intervention, none of the three included studies 
provided sufficient data on the existence or non-existence of adverse and se-
rious adverse events [37, 38, 40]. Safety outcomes were only discussed as part 
of the discussion and conclusion. Out of the nature of sepsis, it is evident that 
potential adverse events are difficult to relate to the procedure, as not enough 
knowledge on the underlying pathophysiologic mechanisms of sepsis exists.  
However, the more important it is for future studies to note potentially non-
related adverse events. In this regard, a registry has been established to track 
and record potential adverse events occurring during or following the use of 
CytoSorb®. Although voluntary, this was regarded as first step towards in-
creased transparency and improved data on safety outcomes [41].  
Overall, there is no evidence for the efficacy and safety of therapeutic use of 
ECAT in patients with sepsis, and very low evidence for its preventive use. 
The quality of evidence is very low in both indications. Although we could 
identify one randomised study, the risk of bias of this study was high, due to 
a small sample size, unclear allocation concealment, insufficient blinding, 
and a high rate of loss to follow-up (30%), without intention to treat analy-
sis. The study sample of the RCT was not powered to draw conclusions on 
mortality, or other patient-relevant benefits. Only one of the two observational 
studies included a control group, however, failed to state patient characteris-
tics. Within the assessed studies, patient relevant outcomes were either not 
reported [38], or incompletely reported [40], or reported as secondary outcome 
measure [37]. Furthermore, safety endpoints were not adequately described 
by any of the studies. The number of patients included in the studies was 
small, and stemmed entirely from single centre studies.  
All studies included a follow-up of maximum 30 days, Born et al. only report-
ed outcomes up until the 5th postoperative day [38]. To date, to the knowledge 
of the authors, neither a study nor an ongoing trial exists assessing the long-
term benefits of the intervention. Since the long-term outcomes of patients 
with sepsis are poor, with frequent re-admission and an increased mortality 
rate following hospital discharge, a follow-up period of at least six months 
would be highly recommendable [21].  
Considering the small study population and the two different indications, as 
preventive treatment during CPB and as therapeutic treatment in patients 
with sepsis or SIRS, the results of the studies cannot be generalised to a larger 
population. Furthermore, the currently available evidence is focused on the 
management of post-CPB SIRS, rather than sepsis or SIRS in general. Further 
details on the applicability of the comprised study evidence can be found in 
Appendix A, Table A-7. 
Notably, one patient of the RCT intervention group died on the 22nd postop-
erative day due to major surgical complications. It is not possible to associate 
this event directly to the intervention itself, nor has this individual event in-
formative value on efficacy or safety. However, since the indication of Cyto-
Sorb® as preventive therapy is to improve post-CPB outcomes and is particu-
larly indicated in cases of surgical complications, it remains to be noted that 
this single event could not be prevented using CytoSorb® therapy, while no 
comparable event occurred in the control group [37].  
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Several authors expressed their concerns that the ECAT itself could also wors-
en the outcomes of patients with sepsis or SIRS due to a removal of anti-in-
flammatory cytokines besides pro-inflammatory ones [41, 42, 45]. It was raised 
that since the timing of the intervention within the phases of sepsis might play 
a pivotal role, too early or too late cytokine removal could be potentially harm-
ful [42].  
The pathophysiological effects of a general cytokine reduction in the mortal-
ity of sepsis are not completely understood. While there have been studies in-
dicating an association between the level of certain cytokines and the mortali-
ty of sepsis, such as IL-6 and TNF- α, there is no clear understanding of the 
actual underlying intracellular pathways [8, 9]. Several theories on the func-
tion of cytokines within sepsis were proposed as cytokinetic and cytotoxic 
model [46]. Yet, until today, the specific role of cytokines in the pathophysi-
ology of sepsis remains controversial and unresolved [8].  
Considering the lacking understanding of the clinical effect of a cytokine re-
duction, it becomes evident that there is a need to reduce these knowledge 
gaps before introducing ECAT as standard procedure, both in sepsis as well 
as during CPB surgery. A reduction of cytokines could improve the haemo-
dynamic stability in patients with sepsis; however, it could also contribute to 
a deterioration of the disease. Evidence on cytokine reduction as primary out-
come measure cannot replace efficacy and clinical benefit assessments. Clin-
ical benefits in patient-relevant outcomes, and in particular improvement in 
mortality rates need to be demonstrated in order to introduce ECAT to clin-
ical practice.  
Further evaluation of ECATs long- term clinical efficacy and complication 
rates is required.  
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
x The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the assessed technology 
extracorporeal haemadsorption with CytoSorb® in patients with sepsis and 
SIRS is effective and safe. The results from ongoing trials and the publica-
tion of the results from completed RCTs will potentially influence the effect 
estimate considerably.  
In total, we identified seven relevant ongoing trials and one patient registry. 
Two of the ongoing trials assess the use of CytoSorb® in patients with sepsis, 
while the others focus on its preventive use during CPB surgery. Five of the 
studies use parallel assignments (including a control group); yet, only one of 
the studies has a double blind study design. Details on ongoing studies can 
be found in Appendix A Table A-8. 
A re-evaluation of the technology is recommended in 2019 to assess inclusion 
for the benefits catalogue 2020. A minimum level of evidence from at least 
one larger randomized controlled trial (n > 100 patients) and several prospec-
tive case-series (n > 20) for each indication should be available at the time 
of re-evaluation.  
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Appendix 
Evidence tables of individual studies  
included for clinical effectiveness and safety 
Table A-1: ECAT during cardiopulmonary bypass surgery: Results from randomized controlled trials 
Author, year Bernardi, 2016 [37, 39] 
Country Austria 
Sponsor Medical University of Vienna; materials partially funded by Cytosorbents Europe GmbH 
Intervention/Product Haemoadsorption with CytoSorb® during CPB 
Comparator No intervention 
Study design Randomised, single-blinded, controlled, single centre, pilot, feasibility study 
Number of pts 46 randomized, 9 drop out before intervention, 37 included (Int: 19 vs Co: 18),  
2 loss to follow up (35 included for primary outcome analysis) 
Inclusion criteria elective cardiac surgical intervention with an expected CBP duration >120 minutes 
Exclusion criteria  Emergency procedures 
 Heart transplantation 
 Elective left ventricular assist device (LVAD) implantation 
 Pulmonary thromboendarterectomy 
 Declined informed consent 
 Serum creatinine > 2mg/dl 
 Body mass index < 18 
 Age < 18 years 
 Pregnant woman 
 Receiving chemotherapy or diagnosed with any disease state (e.g., AIDS)  
that has produced leukopenia 
 Receiving anti leukocyte drugs 
 Receiving TNF-alpha Blockers, immunosuppressive drugs (e.g. tocilizumab) 
 CRP > 2mg/dl 
 History of Stroke 
 Bilirubin >2mg/dl 
Age of patients (yrs)  Mean age: 67 yrs (30-81); Mean age Int: 64(30-81) vs mean age Co:69 (51-81); p=0,1737 
Gender (% female) Total: 11 (29.7%), Int: 7 (36.8%) vs Co:4 (22.2%) 
Primary Outcome Measures Differences in the evolution of cytokines IL-1β, IL-6, IL-18, TNF-α,  
IL-10 during cardiopulmonary bypass 
Secondary Outcome 
Measures 
 Serum CRP changes 
 ex vivo LPS induced TNF-α production 
 Drug treatment Vasopressor dose, Insulin dose 
 Volemic status: Need of fluid components (crystalloid, colloid solutions),  
Need for blood products (erythrocytes, fresh frozen plasma, platelets),  
Body impedance, Body weight 
 Changes in procalcitonin, albumin, fibrinogen and total blood count 
 Length of ICU stay 
 30 days mortality 
Follow-up (months) 30 days 
Loss to follow-up, n (%) 14 (30%), Int:8 vs. Co:6 
Mean CPB time/  
treatment time 
Int: 191 min. (range 112-288min), Co 170 min (83-274) 
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Author, year Bernardi, 2016 [37, 39] 
Outcomes 
Efficacy 
Overall survival, n (%)  36/37 (97,2%); Int: 18/19; Co: 18/18 
MODS score NR 
SOFA score NR. 
Days in ICU Days in ICU Int 2.3 (+/-2) vs. Co 2.4 (+/-1.9), p=0.87 
Days of hospitalisation NR 
Days of ventilator therapy Int 0.7 (+/- 1.6) vs Co 0.2 (+/- 0.4); p=0.19 
Reduction of catecholamine 
support; Reduction of 
vasopressor therapy 
No difference between Int and Co group 
Reduction in IL 6 Levels IL-6 pg/ml: 
 after CBP:Median Int: 62.9 vs Co: 63.6, p= 0.326 
 2 h: Int: 120.8 vs Co: 118.7, p=0.6781 
 24h: Int: 111.6 vs. Co: 120.9, p= 0.9837 
 48h: Int: 89.0 vs Co 120.9, p= 0.3809 
Safety 
Overall complications, n (%) None reported1 
Major AE, n (%)  Int 0/19, co: 0/18 
Minor AE, n (%) Int 0/19, co: 0/18 
1 One patient of the intervention group died on the 22nd postoperative day due to multiple surgical complications 
AE = Adverse effect, CPB = Cardiopulmonary bypass, Co = Control- group, CRP = C-reactive protein,  
ICU = Intensive care Unit, Int = Intervention- group, NR = not reported, PO = primary outcomes, yrs = years 
 
Table A-2: ECAT during and after CPB surgery: Results from observational studies 
Author, year Träger, 2016 [40] Born, 2014 [38] 
Country Germany Germany 
Sponsor University hospital Ulm NR 
Intervention/Product Therapeutic haemoadsorption therapy 
with CytoSorb® post-CPB 
Preventive haemadsorption therapy 
with CytoSorb® during CPB 
Comparator none Conventional cardio-pulmonary bypass 
Study design Single-center retrospective case series 
Datacollection: 05/2013- 10/2014 
Single-center retrospective case series 
Datacollection: Int:02/2013- 11/2013 
Co: 01/2012- 12/2012 
Number of pts 16 40 (20 Int; 20 Co) 
Inclusion criteria Pts post-CPB SIRS within 24h after surgery 
AKIN criteria met, CRRT treatment necessary 
Pts undergoing complex heart surgery 
with hypothermic arrest and antegrade 
cerebral perfusion 
Exclusion criteria NR NR 
Age of patients (yrs)  Mean: 71 (range 53- 84) NR 
Gender (% female) 4 (25%) NR 
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Author, year Träger, 2016 [40] Born, 2014 [38] 
Outcome Measures  IL-6 
 IL-8 
 Lactate 
 Base excess 
 Cardiac index 
 MAP 
 Epinephrine dose (catecholamine dose) 
 Norepinephrine dose  
(catecholamine dose) 
 Days in ICU 
 28-day survival 
 IL-6 
 CRP 
 Procalcitonin 
 Leukocytes 
 Fibrinogen 
Follow-up (days) 28 days 4 days post surgery 
Loss to follow-up, n (%) n.a n.a. 
Mean treatment time  
with CytoSorb® 
34 h (range 5-50h)1 NR 
No. of CytoSorb® treatments 1-3/pts 1/pts 
Outcomes 
Efficacy 
Overall survival, n (%)  10/16 (62%) NR 
MODS score NR NR 
SOFA score NR2 NR 
Days in ICU Days in ICU NR NR 
Days of hospitalisation NR NR 
Days of ventilator therapy NR NR 
Reduction of catecholamine 
support; Reduction of 
vasopressor therapy 
Not reported for all patients  
(only individual data entries) 
NR 
Reduction in IL 6 Levels Not reported for all patients (only 
individual data entries) 
Int vs Co Day 1: 200 ng/l vs 300 ng/l 
Day 2: 110ng/l vs 320 ng/l 
Day 3: 90 ng/l vs 400 ng/l 
Day4: 80ng/l vs 420 ng/l 
Outcomes 
Safety 
Overall complications, n (%) NR NR 
Major AE, n (%)  None reported NR 
Minor AE, n (%) None reported NR 
1 Mean treatment time for the first treatment with cytosorb 
2 SOFA score measured but not reported 
AE = Adverse Event, yrs = years, CRRT = Continuous Renal Replacement Therapy ICU = Intensive Care Unit,  
Pts = Patients, MAP = Mean Arterial Pressure, NR = not reported, n.a. = not applicable, No = number,  
SIRS = Systemic Inflammatory Response Syndrome, 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differ-
ences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Guidelines of EUnetHTA 
[47, 48].  
Table A-3: Risk of bias – study level (randomised studies), Cochrane Risk of bias tool 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Bernardi, 2016;  
NCT01879176 [37] 
Yes Unclear Yes No No No1 high 
1 Few participants, high loss to follow up, no ITT (intention to treat) analysis 
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Table A-4: Risk of bias – study level (case series),  IHE Risk of Bias checklist  
Study reference/ID Träger, 2016 [40] Born, 2014 [38] 
 1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? Yes No 
 2. Are the characteristics of the participants included in the study described? Yes No 
 3. Were the cases collected in more than one centre? No Yes 
 4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? Yes No 
 5. Were participants recruited consecutively? Yes No1 
 6. Did participants enter the study at similar point in the disease? Yes Yes 
 7. Was the intervention clearly described in the study? Yes No 
 8. Were additional interventions (co-interventions) clearly reported in the study? Yes No 
 9. Are the outcome measures clearly defined in the introduction or methods section? Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective methods? Yes No 
 11. Were outcomes measured before and after intervention? No No 
 12. Were the statistical tests used to assess the relevant outcomes appropriate? No No 
 13. Was the length of follow-up reported? Yes No 
 14. Was the loss to follow-up reported? No No 
 15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? No No 
 16. Are adverse events reported? Yes No 
 17. Are the conclusions of the study supported by results? Yes No 
 18. Are both competing interest and source of support for the study reported? Yes No 
Overall Risk of bias Moderate Very high 
1 Recruitment was not reported 
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Table A–5: List of case reports of the application of haemadsorption therapy with CytoSorb® 
Title Author, Year 
Use of a novel haemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study Basu, 2014 [49] 
First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report Bruenger, 2015 [50] 
First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from 
generalized herpes simplex virus 1 infection 
Frimmel, 2014 [51] 
Hemoadsorption using CytoSorb® beads (Cytosorbents) in a cirrhotic patient with septic multiorgan failure Gruber, 2013 [52] 
Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy Hetz, 2014 [53] 
CytoSorb, a novel therapeutic approach for patients with septic shock: a case report Hinz, 2015 [54] 
The Use of a Cytokine Adsorber (CytoSorb) in a Patient with Septic Shock and Multi-Organ Dysfunction (MODS) after a Severe Burn Injury Houschyar, 2016 [55] 
Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton-Valentine leukocidin-positive 
Staphylococcus aureus pneumonia and H1N1 
Lees, 2016 [56] 
Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report Mitzner, 2013 [57] 
Early report: The use of cytosorbTM haemabsorption column as an adjunct in managing severe sepsis: Initial experiences, review and recommendations Morris, 2015 [58] 
Hemoadsorption in Infection-Associated Rhabdomyolysis Suefke, 2016 [59] 
First use of a hemoadsorption device (CytoSorb®) during continous venovenous hemofiltration (CVVH) in a patient undergoing retransplantation with 
ABO incompatible graft for acute graft dysfunction 
Tomescu, 2014 [60] 
First report of cytokine removal using CytoSorb® in severe noninfectious inflammatory syndrome after liver transplantation Tomescu, 2016 [61] 
Cytokine Reduction in the Setting of an ARDS-Associated Inflammatory Response with Multiple Organ Failure Trager, 2016 [62] 
First case of toxic shock treated with haemoadsorption by CytoSorb® in the Netherlands van der Linde, 2016 [63] 
CytoSorb® in a patient with Legionella pneumonia-associated rhabdomyolysis: a case report Wiegele, 2015 [64] 
Can cytokine adsorber treatment affect antibiotic concentrations? A case report Zoller, 2015 [65] 
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Table A-6: Medtech innovation brieifing MIB87, NICE, Summary of evidence (2016) [20] 
Study size,design and 
location 
Intervention and comparator Outcomes Strengths and limitations 
Schädler et al (2013a); 
Schädleret al.(2013b) 
43 patients, Randomised, 
controlled trial 
Multicentre study 
Germany 
Haemoperfusion treatment for 
cytokine removal (CytoSorb) and 
standard care. 
Standard care (control). 
There were no serious devicerelated adverse 
events. There were no differences in 28-day or 
60-day Mortality between CytoSorb® and the 
control. CytoSorb® significantly reduced blood 
concentrations of cytokines. 
Unable to assess the trial quality because it has only been 
published as an abstract in aposter.There was no between-
group comparison ofreduction in cytokines. 
Unclear duration of follow-up. 
Minimal details of the patients. 
Funded by the manufacturer. 
The authors noted the limitation that further research  
is needed to assess the device on clinical outcomes. 
Kogelmann et al. (2015) 
8 patients 
Case series 
Singlecentre study 
Germany 
CytoSorb® as adjunctive therapy. Overall survival was 62.5%. Slight decrease  
in SOFA score and SAPS II. 
Small case series only reported as an abstract, so unable  
to assess study quality.Unclear if data collection was 
prospective or retrospective.  
No comparator group. 
Minimal details of the patients.  
Unclear duration of follow-up. Limited outcomes 
reported. Funding source not reported. May include 
patients from Kogelmann et al (2016) study. 
Kogelmann et al. (2016) 
14 patients 
Case series 
Singlecentre study 
Germany 
CytoSorb® as adjunctive therapy. Overall survival was 35.7%.Survival increased 
if treatment started within 48 hours. 
Small case series only reported as an abstract, so unable  
to assess study quality. 
Unclear if data collection was prospective or retrospective. 
No comparator group. 
Minimal details of the patients. Unclear duration of follow-up. 
Limited outcomes reported. Funding source not reported. 
May include patients from Kogelmann et al. (2015) study. 
Laddomada et al. (2016) 
8 patients 
Case series 
Singlecentre study 
Italy 
CytoSorb® as adjunctivetherapy in 
combination with continuous renal 
replacement therapy. 
Six of 8 patients survived. In survivors, 
procalcitonin levels decreased and renal 
function improved. 
Small case series only reported as an abstract, so unable to 
assess study quality. 
Unclear if data collection was prospective or retrospective. 
No comparator group. Minimal details of the patients. 
Unclearduration of follow-up. Limited outcomes reported. 
Funding source not reported. 
Sathe et al. (2015)  
19 patients 
Case series 
Single centre study 
India 
CytoSorb® as an adjuvant therapy with 
standard care. 
Four of 19 patients with predicted high 
mortality survived. Three of the 4 survivors had 
CytoSorb® in less than 24 hours of admission. 
Almost half of those who died were given 
CytoSorb® more than 24 hours after admission. 
Small retrospective case series only reported as an 
abstract, so unable to assess study quality. No comparator 
group. Minimal details of the patients. Unclear duration of 
follow-up. Limited outcomes reported. Funding source not 
reported. 
SOFA = Sepsis-related Organ Failure Assessment; SAPS = Simplified Acute Physiology Score. 
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Applicability table 
Table A-7: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Prevention of SIRS and sepsis 
The main body of evidence assessed haemadsorption treatment as a preventive measure for patients 
undergoing elective heart surgery with CPB. This presents only a small fraction of patients that are at 
risk of developing SIRS and sepsis. The mean age of these patients is above 70, a patient population 
at higher risk of developing SIRS and sepsis. Minimal invasive heart surgery and off-pump procedures 
are becoming more frequently used, which might also negatively affect the potential of 
haemadsorption therapy during open heart surgery.  
Treatment of SIRS sepsis and septic shock. 
Only one observational study (n=16) covered this patient population, and only assssed patients with 
SIRS. The study included patients following complex heart surgery with SIRS symptomatic and the 
need of continuous renal replacement therapy. Since sepsis and septic shock stem from a wide variety 
of causes, the presented population does not reflect the spectrum of the disease, and differences in 
treatment courses and outcomes.  
Intervention The studies included CytoSorb® as a preventive intervention during CPB heart surgery or following 
CPB. Only very limited information is available on extracorporeal haemadsorption treatment as a 
standalone therapy for the treatment of sepsis. While all studies use the same technology (CytoSorb®), 
the interventions and procedures are highly heterogeneous between studies and cannot be directly 
compared to each other.  
Comparators Only two of the studies included a comparison group, of which one comparison group was historic.The 
comparator was standard of care for the treatment of sepsis and conventional surgery, as there is no 
causal sepsis therapy available to date. Efficacy could not be sufficiently assessed due to the limited 
number of patients included in the studies, and the lack of comparability between studies. 
Outcomes The most frequently reported outcome were changes in IL-6 levels, and inflammatory markers in 
the blood (CRP, Lactate, Procalcitonin). Critical patient related outcomes such as mortality, organ 
function, days in the ICU and days of hospitalisation were presented as secondary outcomes, and 
not statistically tested. Long- term patient benefit was not assessed in any study. Potential harms  
of the technology were only addressed in the discussion and not in the results part of the studies.  
Setting All of the studies were single-center studies based in Europe, two of them were based in Germany. 
The geographical focus of the published literature and of many ongoing trials is Germany and 
German-speaking countries, such as Austria.  
The procedures took place in hospital ICUs and in operating rooms, which reflects the clinical setting 
where the technology is deployed. Clinical expertise with extracorporeal circuits, such as 
haemodialysis devices, is needed.  
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List of ongoing randomised controlled trials 
Table A-8: List of ongoing controlled trials of haemadsorption therapy  
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary completion 
date, current status Sponsor 
NCT00559130 
Efficacy Study of 
CytoSorb® 
Hemoperfusion Device 
on IL-6 Removal in 
ARDS/ALI Patients 
With Sepsis 
ICU patients with septic 
shock of medical origin. 
Acute Respiratory 
Distress Syndrome, 
Acute Lung Injury,  
Sepsis 
Daily haemoperfusion 
for 6 hours with 
CytoSorb® device 
Routine ICU care. Relative IL-6 levels as a 
percent (%) of baseline 
Ventilator Free Days, 
Reduction cytokines  
TNF-Î±, IL-1b, IL-10, CRP, 
28-day all cause mortality, 
Oxygen Index (OI),  
P/F ratios, MODS scores 
June 2011, 
Completed, no results 
available 
MedaSorb 
Technologies, Inc 
NCT02566525 
CytoSorb® Reduction 
of Free Hemoglobin 
During Cardiac Surgery 
(REFRESH) 
Elective, cardiac surgery 
requiring cardio-
pulmonary bypass with 
anticipated duration of 
>180 minutes 
Standard of care plus 
treatment with CytSorb 
device installed on the 
CPB machine 
Standard of care, 
Conventional cardio-
pulmonary bypass 
Change in plasma free 
haemoglobin, Assessment 
of serious device related 
adverse events 
August 2016, 
recruiting 
CytoSorbents, Inc 
NCT02588794 
Cytokine Adsorption  
in Sepsis and Acute 
Kidney Injury (CASAKI) 
Renal Insufficiency or 
Renal Failure &or End-
stage Renal Disease; 
Patients > 18, severe 
sepsis or septic shock 
according to ESICM 
guidelines not older  
than 24 h 
Standart CVVHD plus 
CytoSorb® 300 ml device 
Standart CVVHD RIFLE stadium L or E after 
acute kidney injury related 
to sepsis 
December 2017, 
recruiting 
Technische 
Universität 
München 
NCT02775123 
Cytokine Clearance 
With Cytoabsorbant 
Device During Cardiac 
Bypass (CCCC) 
Myocardial Ischemia 
Heart Valve Diseases, 
Patients planned for 
elective cardiac surgery 
requiring CPB 
Standard of care plus 
treatment with CytSorb 
device installed on the 
CPB machine 
Standard of care, 
Conventional 
cardiopulmonary 
bypass 
Change in Cytokine levels December 2017, 
recruiting 
Centre Hospitalier 
Universitaire 
Vaudois 
NCT02265419 
Use of Extracorporeal 
Treatment With the 
Cytosorb-Adsorber for 
the Reduction of SIRS 
in Heart Surgery 
Patients (CASHSP) 
Multiple Organ Failure Extracorporeal 
treatment with the 
CytoSorb® adsorber for 
24 hours after heart 
surgical operation. 
Historic control 
group 
Significant difference in 
the mean-SOFA 
(Sequential Organ Failure 
Assessment)-score between 
the Cytosorb-group and 
the historic control group 
after 7 days 
March 2017, 
recruiting 
University of 
Rostock 
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NCT02297334 
Removal of Cytokines 
During Extracorporeal 
Circulation in Cardiac 
Surgery 
Coronary Artery Disease, 
Heart Valve Diseases 
CytoSorb device, 
installed into the heart 
lung machine in a 
parallel stream to the 
main circulation. 
No Intervention: 
Patients randomised 
to this arm are 
treated without the 
CytoSorb device 
during bypass 
Change of levels of 
cytokines during 
procedure compared to 
baseline parameters to be 
measured are: interleukin 
(IL) 1, interleukin 6, 
interleukin 8, interleukin 
10, tumor necrosis factor-
alpha 
October 2015 
Ongoing, not 
recruiting 
Universitätsklinikum 
Hamburg-Eppendorf 
DRKS00007928 
Removal of cytokines 
during cardiac surgery, 
RECCAS 
Elective, cardiac  
surgery requiring 
cardiopulmonary bypass 
with anticipated 
duration of >90 minutes 
Standard of care plus 
treatment with CytSorb 
device installed on the 
CPB machine 
Standard of care, 
Conventional cardio-
pulmonary bypass 
Reduction of IL-6 in 
patient serum 
26.01.2015* Universitätsklinikum 
Köln 
NCT02312024 
International Registry 
on the Use of the 
CytoSorb®-Adsorber  
in ICU Patients 
Sepsis; 
Need of Cardiac Surgery 
Device: Use of 
CytoSorb® adsorber 
Observational study 
design 
Difference between 
mortality predicted by 
scoring systems (APACHE 
II/SAPS II, EuroSCORE II) 
and actual mortality 
within 30 days after 
intervention 
December 2020 
Recruiting 
Jena University 
Hospital 
University Hospital 
Goettingen 
* enrolment date of the first patient 
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Literature search strategies 
Search strategy for Medline via OVID 
Database: Ovid MEDLINE(R) Epub Ahead of Print <December 22, 2016>, Ovid MEDLINE(R)Ovid MEDLINE(R) 
<1946 to December Week 1 2016>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 22, 
2016>, Ovid MEDLINE(R) Daily Update <December 07, 2016> 
Search Strategy: 
1 exp Sepsis/(116433) 
2 Severe Sepsis*.mp. (7987) 
3 exp Shock, Septic/(21930) 
4 Septic Shock*.mp. (19195) 
5 Abdominal septic*.mp. (129) 
6 Septic Arthrit*.mp. (5176) 
7 exp Systemic Inflammatory Response Syndrome/(120203) 
8 SIRS.ti,ab. (4786) 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (136554) 
10 exp Cytokines/(696951) 
11 exp Adsorption/(56264) 
12 10 and 11 (598) 
13 (Cytokine* adj5 (Adsorption* or Adsorb*)).mp. (161) 
14 exp Hemadsorption/(1016) 
15 H?em?adsor*.mp. (1843) 
16 Extra?corporeal blood purif*.mp. (157) 
17 (Cytokine* adj5 filt*).mp. (122) 
18 Cyto?Sorb*.mp. (25) 
19 (Cytokine* adj5 Remov*).mp. (586) 
20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (3252) 
21 9 and 20 (249) 
22 remove duplicates from 21 (227) 
Search date: 23th December 2016 
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Search strategy for Embase 
No. Query Results  Results Date 
#30 ‘sepsis’/exp OR ‘severe sepsis*’:ti,ab OR ‘septic shock’/exp OR ‘septic 
shock*’:ti,ab OR ‘abdominal septic’:ti,ab OR ‘septic arthrit*’:ti,ab OR 
‘systemic inflammatory response syndrome’/exp ORsirs:ti,ab AND 
(‘cytokine’/exp AND ‘adsorption’/exp OR (cytokine* NEAR/5 (adsorption* 
OR adsorb*)):ab,ti OR ‘hemadsorption’/exp OR hemadsor*:ti,ab OR 
hemaadsor*:ti,ab OR hemoadsor*:ti,ab OR ‘hemo adsor*’:ti,ab OR 
‘haemoadsor*’:ti,ab OR ‘haemadsor*’:ti,ab OR ‘haemo-adsor*’:ti,ab OR 
‘extracorporeal blood purif*’:ti,ab OR ‘extra-corporeal blood purif*’:ti,ab 
OR (cytokine* NEAR/5 filt*):ti,ab OR cytosorb:tn,dn OR ‘cyto sorb*’ OR 
cytosorb* OR (cytokine* NEAR/5 remov*):ti,ab) 
400 23 Dec 2016 
#29. ‘cytokine’/exp AND ‘adsorption’/exp OR (cytokine*NEAR/5 (adsorption* 
OR adsorb*)):ab,ti OR’hemadsorption’/exp OR hemadsor*:ti,ab OR 
hemaadsor*:ti,ab OR hemoadsor*:ti,ab OR ‘hemo adsor*’:ti,ab OR 
‘haemoadsor*’:ti,ab OR ‘haemadsor*’:ti,ab OR ‘haemo-adsor*’:ti,ab 
OR’extracorporeal blood purif*’:ti,ab OR ‘extra-corporeal blood 
purif*’:ti,ab OR (cytokine* NEAR/5 filt*):ti,ab OR cytosorb:tn,dn OR ‘cyto 
sorb*’ OR cytosorb* OR (cytokine* NEAR/5 remov*):ti,ab 
3,493 23 Dec 2016 
#28. (cytokine* NEAR/5 remov*):ti,ab 669 23 Dec 2016 
#27. cytosorb*  66  23 Dec 2016 
#26. ‘cyto sorb*’ 3 23 Dec 2016 
#25 cytosorb:tn,dn 26 23 Dec 2016 
#24. (cytokine* NEAR/5 filt*):ti,ab 133 23 Dec 2016 
#23.  ‘extra-corporeal blood purif*’:ti,ab  6 23 Dec 2016 
#22. ‘extracorporeal blood purif*’:ti,ab 196 23 Dec 2016 
#21. ‘haemo-adsor*’:ti,ab 1 23 Dec 2016 
#20. ‘haemadsor*’:ti,ab 201 23 Dec 2016 
#19. haemoadsor*’:ti,ab  12 23 Dec 2016 
#18. ‘hemo adsor*’:ti,ab 3 23 Dec 2016 
#17. hemoadsor*:ti,ab 106 23 Dec 2016 
#16. hemaadsor*:ti,ab 0 23 Dec 2016 
#15. hemadsor*:ti,ab 720 23 Dec 2016 
#14. ‘hemadsorption’/exp  913 23 Dec 2016 
#13. (cytokine* NEAR/5 (adsorption* OR adsorb*)):ab,ti 191 23 Dec 2016 
#12. ‘cytokine’/exp AND ‘adsorption’/exp 1,019 23 Dec 2016 
#11. ‘adsorption’/exp 74,050 23 Dec 2016 
#10. ‘cranial nerve’/exp  89,666 23 Dec 2016 
#9. ‘sepsis’/exp OR ‘severe sepsis*’:ti,ab OR ‘septic shock’/exp OR ‘septic 
shock*’:ti,ab OR ‘abdominal septic’:ti,ab OR ‘septic arthrit*’:ti,ab OR 
‘systemic inflammatory response syndrome’/exp OR sirs:ti,ab 
225,193 23 Dec 2016 
#8. sirs:ti,ab 6,826 23 Dec 2016 
#7. systemic inflammatory response syndrome’/exp 213,783 23 Dec 2016 
#6. ‘septic arthrit*’:ti,ab 5,723 23 Dec 2016 
#5. ‘abdominal septic’:ti,ab 151 23 Dec 2016 
#4. ‘septic shock*’:ti,ab 25,893 23 Dec 2016 
#3. ‘septic shock’/exp 40,246 23 Dec 2016 
#2. ‘severe sepsis*’:ti,ab 11,603 23 Dec 2016 
#1. ‘sepsis’/exp  208,559 23 Dec 2016 
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Search strategy for CRD  
#### Cytokine Adsorption in Septic Patients 
1 (Cytokine* NEAR (Adsorption* OR Adsorb*)) 
2 MeSH DESCRIPTOR Cytokines EXPLODE ALL TREES 
3 MeSH DESCRIPTOR Hemadsorption EXPLODE ALL TREES 
4 (Hemadsor*) 
5 (Haemadsor*) 
6 (Haemoadsor*) 
7 (Haemo-adsor*) 
8 (Blood NEAR purif*) 
9 (Cytokine* NEAR filt*) 
10 (CytoSorb*) 
11 (Cyto-Sorb*) 
12  (Cytokine* NEAR Remov*) 
13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
14 MeSH DESCRIPTOR Sepsis EXPLODE ALL TREES 
15  (Sepsis*) 
16 MeSH DESCRIPTOR Shock, Septic EXPLODE ALL TREES 
17 (Septic) 
18 MeSH DESCRIPTOR Systemic Inflammatory Response Syndrome EXPLODE ALL TREES 
19 (SIRS) 
20 #14 OR #15 OR #16 OR #17 OR #18 OR #19 
21 #13 AND #20 
31 Hits 
Search date: 23th December 2016 
 
 
Search strategy for Cochrane 
Search Name: Cytokine Adsorption in Septic Patients 
Search Date: 23/12/2016 22:13:21.858 
ID Search 
#1 MeSH descriptor: [Sepsis] explode all trees 
#2 Severe Sepsis* (Word variations have been searched) 
#3 MeSH descriptor: [Shock, Septic] explode all trees 
#4 Septic Shock* (Word variations have been searched) 
#5 Abdominal sep* (Word variations have been searched) 
#6 Septic Arthrit* (Word variations have been searched) 
#7 MeSH descriptor: [Systemic Inflammatory Response Syndrome] explode all trees 
#8 SIRS:ti,ab,kw (Word variations have been searched) 
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 
#10 MeSH descriptor: [Cytokines] explode all trees 
#11 MeSH descriptor: [Adsorption] explode all trees 
#12 #10 and #11 
#13 Cytokine* near (Adsorption* or Adsorb*):ti,ab,kw (Word variations have been searched) 
#14 MeSH descriptor: [Hemadsorption] explode all trees 
#15 Haemadsor* (Word variations have been searched) 
Extracorporeal cytokine haemadsorption therapy 
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#16 Haemadsor* (Word variations have been searched) 
#17 Hemo-adsor* (Word variations have been searched) 
#18 Haemo-adsor* (Word variations have been searched) 
#19 Hemadsor* (Word variations have been searched) 
#20 blood near purif*:ti,ab,kw (Word variations have been searched) 
#21 Cytokine* near filt*:ti,ab,kw (Word variations have been searched) 
#22 CytoSorb* (Word variations have been searched) 
#23 Cyto-Sorb* (Word variations have been searched) 
#24 Cytokine* near Remov*:ti,ab,kw (Word variations have been searched) 
#25 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 
#26 #9 and #25 
Total: 41 Hits 
 
 
Search strategy for PubMed 
PubMed Suchstring: 
(((Sepsis OR Severe Sepsis[tiab] OR Septic Shock OR Abdominal sepsis[tiab] OR Septic Arthritis[tiab] OR Systemic 
Inflammatory Response Syndrome OR SIRS[tiab]))) AND ((Cytokine Adsorption[tiab] OR Hemadsorption OR 
Extracorporeal blood purification[tiab] OR Cytokine Filter[tiab] OR Cytokine Filtration[tiab] OR Cytokine 
Removal[tiab] OR CytoSorb[tiab] OR cytosorbent[tiab])) 
261 Hits 
Search date: 23st December 2016 
 
 

  
 
 
 
 
